Final Program - Canadian Society of Hospital Pharmacists

Let’s get our 

feet wet! 

On se mouille! 

Charlottetown 

Premiere 

Charlottetown 

Une première 

6 5 T H S U M M E R E D U C A T I O N A L S E S S I O N S 6 5 E S S É A N C E S É D U C A T I V E S D ’ É T É 

D E L T A P R I N C E E D W A R D H O T E L , C H A R L O T T E T O W N , P R I N C E E D W A R D I S L A N D 

FINAL PROGRAM 

PROGRAMME FINAL

What is CSHP 2015? 

● Vision of pharmacy practice excellence in the year 2015 

● Strategic objective of CSHP’s Vision 2014 which aims to improve 

patient medication outcomes and safety by advancing practice 

excellence 

● A quality care initiative 

● A project aiming to answer the questions… “What would make the 

most difference to our patients?” and “What will convey the positive 

contributions of the pharmacist?” 

● Six specific goals that will guide practitioners towards the CSHP vision 

● Sub-objectives that include measurable targets with established 

baselines used to monitor progress, which can be reviewed and 

revised as practice goals change 

Qu’est-ce que le projet SCPH 2015? 

● Une vision de l’excellence en pratique pharmaceutique en l’an 2015 

● Un objectif stratégique de la Vision 2014 de la SCPH, lequel s’applique 

à améliorer les résultats et la sécurité de la pharmacothérapie des 

patients en faisant avancer l’excellence en pratique. 

● Un projet axé sur la qualité des soins 

● Un projet qui vise à répondre aux questions suivantes : « Qu’est-ce qui 

serait le plus profitable pour nos patients? Qu'est ce qui permettrait de 

communiquer les contributions positives du pharmacien? » 

● Six buts précis qui aideront les pharmaciens à concrétiser la vision de la 

SCPH 

● Des objectifs sous-jacents qui sont assortis de cibles mesurables nous 

permettant d'établir un point de référence et de suivre les progrès, et 

qui pourront être réexaminés et modifiés à mesure que les objectifs et 

les lignes directrices de la pratique changent 

CSHP 

Targeting Excellence in Pharmacy Practice 

Goals 

1Increase 2Increase 3Increase 4 

Increase 

5Increase 6Increase the extent to which pharmacists help individual hospital 

inpatients achieve the best use of medications 

the extent to which pharmacists help individual nonhospitalized 

patients achieve the best use of medications 

the extent to which hospital and related healthcare setting 

pharmacists actively apply evidence-based methods to the 

improvement of medication therapy 

the extent to which pharmacy departments in hospitals and 

related healthcare settings have a significant role in improving the 

safety of medication use 

the extent to which hospitals and related healthcare settings 

apply technology effectively to improve the safety of medication use 

the extent to which pharmacy departments in hospitals and 

related healthcare settings engage in public health initiatives on 

behalf of their communities 

To get started on CSHP 2015 now, go to CSHP’s website at www.cshp.ca. 

There you will find the complete list of goals and objectives, a selfassessment 

tool, PowerPoint presentations and more. 

*CSHP 2015 was adapted with permission from the ASHP 2015 Initiative. 

Canadian Society of Hospital Pharmacists 

Société canadienne des pharmaciens d’hôpitaux 

SCPH 

Point de mire sur l’excellence en pratique pharmaceutique 

Buts 

1 

Accroître 

le degré d'intervention des pharmaciens auprès de 

chaque patient hospitalisé afin d'assurer l'utilisation optimale des 

médicaments. 

2Accroître le degré d'intervention des pharmaciens auprès de la 

clientèle non hospitalisée afin d'assurer une utilisation optimale des 

médicaments. 

3Étendre l'application du principe des décisions fondées sur les 

preuves à la pratique clinique quotidienne des pharmaciens des 

établissements de santé dans le but d'améliorer la pharmacothérapie 

4Accroître le rôle joué par les départements de pharmacie des 

établissements de santé dans l'amélioration de l'utilisation sécuritaire 

des médicaments. 

5Étendre l'application efficace des technologies dans les 

départements de pharmacie des établissements de santé pour 

améliorer l'utilisation sécuritaire des médicaments. 

6Accroître le degré d'intervention des départements de pharmacie 

des établissements de santé dans la mise en oeuvre d'initiatives de 

santé publique. 

Pour vous engager dès maintenant dans le projet SCPH 2015, visitez le 

site Web de la SCPH au www.cshp.ca. Vous y trouverez une liste 

complète des buts et des objectifs du projet, un outil d’autoévaluation, 

des présentations PowerPoint et d'autres renseignements. 

*Le projet SCPH 2015 est une adaptation approuvée de l’ASHP 2015 Initiative. 

www.cshp.ca

4 

Dear Colleague: 

It is with great pleasure that we welcome you to the 2012 Summer Educational Sessions (SES) of the 

Canadian Society of Hospital Pharmacists (CSHP), in Charlottetown, Prince Edward Island, “SES By the 

Beach so Let’s Get Our Feet Wet”. 

The Educational Services Committee, under the guidance of Chair Margaret Ackman, has developed an 

educational program that includes the popular Pharmacy Issues and Controversies Forum, CSHP 2015 

Success Stories, Leadership Pearls and Strategies, and Infectious Disease PSN Session. For more 

educational content please refer to pages 11 through 14. 

Our annual booth decorating theme for this year is “SES by the Beach”. Please take time to visit the 

exhibitors to learn from their expertise, and at the same time, acknowledge the tremendous support they 

provide for our conference. While networking and previewing the exhibitors’ latest products, members are 

invited to participate in events planned by the Host Task Force. 

The CSHP 2012 Annual General Meeting (AGM) is scheduled for Sunday, August 12, at 3:10 p.m. At the 

AGM, members will be updated on the many significant initiatives to advance hospital pharmacy practice 

that CSHP National and its branches have been involved with this year, and given a sneak preview of 

plans for next year. 

This year’s social events kick off on Saturday, August 11, with the 16th Annual CSHP Foundation 

Fundraising Golf Tournament, to be held at Fox Meadow Golf and Country Club. This will be the 

Foundation’s last golf event at SES, so we would like to thank our members, non-members and industry 

partners who have participated in the event over the years. All profits will be donated to the R&E 

Foundation, supporting the practice-based research initiatives and targeted education programs of CSHP’s 

members. 

To ensure you have fun while at the conference, the SES Host Task Force, co-chaired by Iain Smith and 

Jennifer Boswell, has organized many social activities, including an early morning 5K Fun Run/3K Walk 

Event; Fun Night at the beach; and our annual Past Presidents’ Dinner and Dance. Tickets are required for 

Fun Night and the Past Presidents’ Dinner – have you got yours? The outstanding efforts of this year’s 

Host Task Force guarantee a memorable time for everyone. 

We hope you enjoy SES in Charlottetown! 

Janice Munroe 

BScPhm 

CSHP President 

Myrella Roy 

BScPhm, PharmD, FCCP 

Executive Director

5 

Cher collègue, Chère collègue, 

C’est avec un immense plaisir que nous vous souhaitons la bienvenue à Charlottetown à l’Île-du-Prince- 

Édouard, à l’occasion des séances éducatives d’été (SÉÉ) 2012 de la Société canadienne des 

pharmaciens d’hôpitaux (SCPH), “SÉÉ à la plage, alors, on se mouille.” 

Le comité des services éducatifs, sous la gouverne de sa présidente, Margaret Ackman, vous a préparé 

tout un programme de formation qui inclut entre autres le populaire forum de discussion sur les 

controverses et les enjeux en pharmacie, des réussites dans le cadre de l’initiative SCPH 2015, des trésors 

et stratégies de leadership et la séance du RSP en infectiologie. Pour en savoir plus sur ce volet éducatif, 

veuillez consulter les pages 11 à 14. 

Cette année, le thème de la décoration des stands sera « SÉÉ à la plage ». Nous vous encourageons à 

prendre le temps de visiter le hall d’exposition afin de tirer avantage de l’expertise des exposants et de 

reconnaître l’important soutien qu’ils apportent à notre congrès. Tout en tissant des liens et en explorant 

les nouveaux produits et services offerts par les exposants, les membres seront invités à prendre part aux 

activités qui ont été préparées par le groupe de travail hôte. 

L’Assemblée générale annuelle (AGA) 2012 de la SCPH se tiendra le dimanche 12 août à 15 h 10. Au 

cours de cette réunion, les membres pourront obtenir un compte-rendu des nombreux projets majeurs 

qui ont permis à la Société et à ses sections de contribuer au progrès de la pharmacie d’hôpital au cours 

de la dernière année et avoir un bref aperçu des plans pour l’année qui vient. 

Cette année, les activités sociales commencent le samedi 11 août par le 16e tournoi de golf annuel de la 

Fondation. Celui-ci se tiendra au Fox Meadow Golf and Country Club et ce sera le dernier tournoi de golf 

de la Fondation organisé dans le cadre des SÉÉ. C'est pourquoi, nous tenons à remercier nos membres, 

nos partenaires de l'industrie et tous les non-membres qui ont participé à cet événement au cours des 

années. Tous les profits de cet événement seront remis à la Fondation pour la recherche et l'éducation 

afin d'appuyer des projets de recherche fondés sur la pratique et des programmes éducatifs ciblés menés 

par des membres de la SCPH. 

Pour s’assurer que vous vous amusez bien pendant le congrès, le groupe de travail hôte des SÉÉ, 

coprésidé par Iain Smith et Jennifer Boswell, vous a préparé plusieurs autres activités sociales, dont une 

course de 5 km ou une marche de 3 km pour les lève-tôt; une partie de plaisir à la plage et le dîner 

dansant annuel des anciens présidents. Il vous faudra des billets pour la partie de plaisir et le dîner des 

anciens présidents… Avez-vous les vôtres? Grâce aux efforts déployés par le groupe de travail hôte, les 

moments que nous partagerons seront certainement mémorables. 

Nous espérons que vous profiterez des SÉÉ 2012 de Charlottetown. 

Janice Munroe 

Myrella Roy 

B. Sc. Pharm. B. Sc. Phm., Pharm. D., FCCP 

Présidente de la SCPH 

Directrice générale

6 

Table of Contents 

Table des matières 

CSHP 

SCPH 

CSHP Staff 

Personnel de la SCPH.....................................................................................6 

Executive and Council 

Bureau de direction et Conseil....................................................................7 

CSHP Staff 

Personnel de la SCPH 

Executive Director 

Directrice générale 

Myrella Roy 

Operations Manager 

Gérante des opérations 

Laurie Frid 

Finance Administrator 

Agente des finances 

Anna Dudek 

Publications Administrator 

Agente des publications 

Colleen Drake 

With Thanks 

Remerciements 

CSHP Hospital Corporate Members 

Entreprises membres du secteur hospitalier..........................................7 

CSHP Industry Corporate Members 

Entreprises membres du secteur de l’industrie ....................................9 

CSHP Sponsors 2011 

Commanditaires de la SCPH en 2011.....................................................9 

The Educational Services Committee 

Le Comité des services éducatifs.............................................................10 

SES 2012 Host Task Force 

Groupe de travail hôte des SÉÉ 2012 ...................................................10 

Faculty 

Conférenciers ..................................................................................................36 

Conference Information 

Information sur la conférence 

Continuing Education Credits 

Crédits de formation continue ..................................................................10 

SES 2012 at a Glance 

SÉÉ 2012 d’un coup d’œil .........................................................................11 

Upcoming Events 

Événements à venir ......................................................................................26 

PPC 2013 Call for Abstracts 

Demande de résumés pour la CPP 2013............................................33 

SES Social Events 

Activités sociales des SÉÉ ...........................................................................42 

Program 

Programme 

Program of Events 

Programme des événements....................................................................11 

Speaker Abstracts 

Résumés des conférenciers.......................................................................15 

Poster Abstracts 

Résumés des affiches ..................................................................................26 

Exhibitor List 

Liste des exposants.......................................................................................40 

Coordinator, Professional 

& Membership Affairs 

Coordonnatrice, Affaires 

professionnelles et service 

aux membres 

Cathy Lyder 

Executive Assistant 

Adjointe de direction 

Rosemary Pantalone 

Conference & PSN 

Administrator 

Agente des congrès et des 

RSP 

Desarae Davidson 

Membership & Awards 

Administrator (on leave) 

Agente du service aux 

membres et des prix 

(en congé) 

Robyn Rockwell 

Interim Membership & 

Awards Administrator 

Agente par intérim du 

service aux membres et 

des prix 

Cheryl Mallory 

CHPRB & Advocacy 

Administrator 

Agente du CCRPH et de la 

valorisation 

Gloria Day 

Web Administrator 

Agente du Web 

Olga Chrzanowska 

Ontario Branch 

Administrator 

Agente de la section de 

l’Ontario 

Susan Korporal 

Interim Office 

Administrator (CSHP 2015 

& Board of Fellows) 

Agente de bureau par 

intérim (SCPH 2015 et 

Conseil des associés) 

Pamela Saunders 

CSHP 2015 Project 

Coordinator 

Coordonnatrice du projet 

SCPH 2015 

Carolyn Bornstein 

CSHP Research and 

Education Foundation 

Administrator 

Agente de la Fondation 

pour la recherche et 

l’éducation de la SCPH 

Janet Lett 

Summer Pharmacy Intern 

Stagiaire en pharmacie 

d’été 

Wenya Miao

7 

Executive Committee 

Bureau de direction 

President 

Présidente 

Janice Munroe 

Fraser Health 

Langley, BC 

President Elect 

Président designé 

Doug Sellinger 

Regina Qu’Apelle Health Region 

Pasqua Hospital Site 

Regina, SK 

Past President 

Président sortant 

Neil MacKinnon 

Dalhousie University 

Halifax, NS 

Director of Finance 

Directeur des finances 

Patrick Fitch 

Victoria General Hospital 

Winnipeg, MB 

Executive Director 

Directrice générale 

Myrella Roy 


Société canadienne des pharmaciens 

d’hôpitaux 

Ottawa, ON 

Council 

Conseil 

British Columbia 

Colombie-Britannique 

Bruce Millin 

Fraser Health Authority 

Langley, BC 

Alberta 

Sheri Koshman 

University of Alberta 

Edmonton, AB 

Saskatchewan 

Donald Kuntz 

Regina Qu’Appelle Health Region 

Regina, SK 

Manitoba 

Albert Eros 

Winnipeg Regional Health Authority 

Winnipeg, MB 

Ontario – Senior/Principale 

Rita Dhami 

London Health Sciences Centre 

London, ON 

Ontario – Junior/Débutant 

Olavo Fernandes 

University Health Network 

Toronto, ON 

Quebec 

Québec 

Diem Vo 

Hôpital Pierre-Boucher 

Longueuil, QC 

New Brunswick 

Nouveau-Brunswick 

Faith Louis 

Horizon Health Network 

Fredericton, NB 

Nova Scotia 

Nouvelle-Écosse 

Theresa Hurley 

QEII Health Sciences Centre 

Halifax, NS 

Prince Edward Island 

Île-du-Prince-Édouard 

Amy Cheverie 

Kings County Memorial Hospital 

Montague, PE 

Newfoundland and Labrador 

Terre-Neuve-et-Labrador 

Tiffany Lee 

General Hospital, Health Sciences Centre 

St. John’s, NL 

Student Delegate 

Déléguée des étudiants 

Megan Riordon 


Halifax, NS 

2011-2012 CSHP Hospital Corporate Members (at time of printing) 

2011-2012 Entreprises membres du secteur hospitalier (au moment de l’impression) 

• Alberta Health Services 

• Horizon Health Network 

• Interior Health 

• Lakeridge Health Network 

• London Health Sciences Centre 

• Medbuy Corporation 

• Northern Health 

• St. Michael's Hospital 

• The Royal Victoria Hospital of Barrie 

• University Health Network

CSHP Research 

and Education 

Foundation 

Unlock the future... 

you are the key 

Fondation pour la 

recherche et l’éducation 

de la SCPH 

Ouvrez les portes à l’avenir... 

Vous en êtes la clé 

2012 Grant Competition 

The CSHP Foundation is pleased to announce the availability of funding for a research grant(s) 

for the 2012 Research Grant Competition. It is important to acknowledge the CSHP Vision 

2014 Statement which broadly describes the vision of CSHP, and the Research Committee: 

“Equipping pharmacists to practice to their full scope, advocating for the profession, 

collaborating with critical stakeholders and fostering engagement and networking 

amongst our members” 

Novice Researcher Funds Available! 

Call for 

Applicants! 

Of the available funds, 25% (or a minimum of $2,500) will be allocated to Novice 

Researchers. The Novice Researcher applicant must have previously been the 

principal investigator for fewer than 3 research publications AND fewer than 

5 different research presentations (podium or poster). “Principal investigator” 

is defined as the first author of the publication or the primary investigator of the 

project. A “research publication” is defined as a full peer-reviewed manuscript 

(with typical sections of Introduction, Methods, Results, and Discussion) that is 

not an abstract, a case report or case series, or a review article. The grant 

application will be judged according to the criteria established for the CSHP 

Foundation Grant Competition. It is not necessary that the Novice Researcher 

Grant consider the priority research topic. The remainder of the funds will be 

available for projects in any area of research related to the pharmaceutical 

sciences or pharmacy practice. 

Selection will be based on a written proposal and budget that conforms to the 

guidelines available from the Foundation. Each submission will be objectively 

evaluated and ranked by reviewers external to the Foundation. Please contact the 

Chair or one of the members of the Mentorship Sub-Committee for inquiries in 

preparing your submission. 

Please note: The Researcher agrees, at the conclusion of the Research Project, to 

submit the results thereof in a form suitable for publication, to a recognized scientific 

journal for publication. The Researcher further agrees to use his or her best efforts to 

have the results of the Research Project published. 

More information, including the “Application for Grants”, Criteria and Submission Checklist”, 

and “Criteria for Evaluation of Submissions” please visit the CSHP Foundation website at 

www.cshpfoundation.ca. 

NEW: All submissions are to be sent electronically (pdf) to Desarae Davidson, CSHP 

National Office at ddavidson@cshp.ca. The deadline for submissions by the Foundation is 

October 14, 2012.

9 

CSHP Sponsors 2011 

The following list reflects all CSHP Sponsorship received from January 1 to December 31, 2011. 

Commanditaires de la SCPH en 2011 

La liste suivante reflète toutes les commandites reçues du premier janvier au 31 décembre 2011. 

Diamond Sponsor 

Commanditaires diamant 

$80,000 or greater 

80 000 $ et plus 

Platinum Sponsor 

Commanditaires platine 

$60,000 - $79,999 

• Hospira Healthcare Corporation 

Gold Sponsor 

Commanditaires or 

$40,000 - $59,999 

• Boehringer-Ingelheim Canada Ltd. 

• Eli Lilly Canada Inc. 

• TEVA Canada 

Silver Sponsor 

Commanditaires argent 

$20,000 - $39,999 

• Apotex Inc. 

• AstraZeneca Canada 

• Bayer Inc. 

• Johnson & Johnson Family of 

Companies 

• Merck Canada Inc. 

Bronze Sponsor 

Commanditaires bronze 

$10,000 - $19,999 

• Abbott Laboratories Inc. 

• Mylan Pharmaceuticals 

• Pendopharm, a division of 

Pharmascience Inc. 

• Sanofi-aventis Canada Inc. 

Donor Sponsor 

Commanditaires donateurs 

$1000 - $9,999 

• Alveda Pharma 

• AmeriscourceBergen Canada 

• Amgen Canada Inc. 

• Astellas Canada Inc. 

• ATP a TCP Company 

• B Braun Medical Inc. 

• Baxa Corporation 

• Baxter Corporation 

• Bristol-Meyers Squibb Canada 

• Canadian Agency for Drug and 

Technologies in Health (CADTH) 

• Caverly Consulting Group 

• Canadian Pharmaceutical Distribution 

Network (CPDN) 

• Canadian Patient Safety Institute (CPSI) 

• Galenova Inc. 

• Healthmark Ltd. 

• HealthPro 

• Hoffmann-La Roche Limited 

• HSBC 

• LEO Pharma Inc. 

• Lexicomp Inc. 

• Lundbeck Canada Inc. 

• Manrex Ltd. 

• McKesson Canada 

• Medbuy 

• National Defence (DND) 

• Northwest Telepharmacy 

• Novartis Pharma Canada 

• Omega Laboratories Limited 

• Ontario College of Pharmacists (OCP) 

• PCCA Canada 

• Pharmacy Examining Board (PEBC) 

• RxFiles – Academic Detailing Program 

• Servier Canada Inc. 

• Shoppers Drug Mart Specialty Health 

• St. Paul’s Hospital 

• Sterimax Inc. 

• Swisslog Healthcare Solutions 

2011-2012 CSHP Industry Corporate Members (at time of printing) 

2011-2012 Entreprises membres du secteur de l’industrie (au moment de l’impression) 

• Amgen Canada Inc. 

• AstraZeneca Canada Inc. 

• Bayer Inc. 

• Canadian Pharmaceutical Distribution 

Network 

• Eli Lilly Canada Inc. 

• Fresenius Kabi Canada 

• Galenova Inc. 

• Healthmark Ltd. 

• Hospira Healthcare Corporation 

• Janssen Inc. 

• LifeScan Canada 

• McKesson Canada Corporation 

• Merck Frosst Canada Limited 

• Omega Laboratories Ltd. 

• Pfizer Canada Inc. 

• Pharmaceutical Partners of Canada, A 

Company of the Fresenius Kabi Group 

• Pendopharm, a Division of 

Pharmascience Inc. 

• Pharmascience Inc. 

• Sandoz Canada Inc 

• Sanofi-aventis Canada Inc. 

• Shoppers Drug Mart Specialty Health 

Network 

• TEVA Canada

10 


Le Comité des services éducatifs 

Chairperson 

Présidente 

Margaret Ackman, PharmD, 

FCSHP 

Alberta Health Services 

Edmonton, AB 

Members 

Membres 

Toni Bailie, BScPhm 

Mount Sinai Hospital 

Toronto, ON 

Claudia Bucci, PharmD 

Sunnybrook Health Sciences 

Centre 

Toronto, ON 

Allison Callaghan, BScPhm 

QEII Health Sciences Centre 

Halifax, NS 

Roxane Carr, PharmD, BCPS, 

FCSHP 

BC Children’s and Women’s 

Health Centre 

Vancouver, BC 

Clarence Chant, PharmD, 

FCSHP 

St. Michael’s Hospital 

Toronto, ON 

Elaine Chong, PharmD, BCPS 

BC Ministry of Health Services 

New Westminster, BC 

Judy Chong, BScPhm 

Royal Victoria Hospital of Barrie 

Barrie, ON 

Olavo Fernandes, PharmD, 

FCSHP 


Toronto, ON 

Alfred Gin, PharmD, FCSHP 

Health Sciences Centre 

Winnipeg, MB 

Kat Timberlake, PharmD 

The Hospital for Sick Children 

Toronto, ON 

Erica Wang, BScPhm, PharmD 

Kelowna General Hospital 

Kelowna, BC 

SES 2012 Host Task Force 

Groupe de travail hôte des SÉÉ 2012 

Co-Chairpersons 

Coprésidents 

Iain Smith, BScPhm, ACPR, CHE 

Queen Elizabeth Hospital 

Health PEI 

Charlottetown, PEI 

Jennifer Boswell, BScPhm 



Members 

Membres 

Beth Bradley, BScPhm 



Rebecca Campbell, BScPhm 



Amy Cheverie, BScPhm 

Kings County Memorial Hospital 

Montague, PEI 

Wendy Cooke, BScPhm 



Marsha Cusack, BScPhm 

Health PEI 


Kelly Herget, BScPhm 

Western Hospital 

Alberton, PEI 

Betty Hutt 

Western Hospital 

Alberton, PEI 

Beverly Martin, BScPhm 

Prince County Hospital 

Summerside, PEI 

Danielle Mill, BScPhm 

Souris Hospital 

Souris, PEI 

Continuing Education Credits 

The Educational Services 

Committee 


of CSHP is comprised of a core 

committee of 15 CSHP members as 

well as corresponding members from the CSHP branches. 

Goal: 

To provide registrants with quality educational sessions. 

Objectives: 

• To provide educational sessions which inform, educate and 

motivate clinical practitioners and leaders 

• To showcase hospital pharmacy practice by presenting sessions 

on innovative pharmacists’ roles, pharmacy practice and 

pharmacy programs 

• To promote life-long learning skills through active participation 

in problem-based workshops 

• To provide registrants with networking and sharing opportunities 

through the exhibits program and poster sessions 

• To provide an opportunity for Pharmacy Specialty Networks 

(PSNs) to meet and share expertise with others 

Crédits de formation continue 

Le comité des services éducatifs 

Le Comité des services éducatifs accueille 15 membres de la 

SCPH et des membres correspondants provenant des sections 

de la SCPH. 

But : 

Présenter des conférences éducatives de qualité aux participants. 

Objectifs : 

EP C.C.E.P. 

Canadian Council on 

Continuing Education in 

Pharmacy 

• Présenter aux personnes inscrites des conférences éducatives 

susceptibles d’informer, d’instruire et de motiver les cliniciens et 

les gestionnaires. 

• Orienter la pratique en pharmacie hospitalière en présentant 

des conférences sur les nouveautés touchant le rôle du 

pharmacien, la pratique de la pharmacie et les programmes de 

pharmacie. 

• Développer des habiletés pour un apprentissage continu par 

une participation active à des ateliers de formation axés sur la 

résolution de problèmes. 

• Donner aux participants des occasions de réseautage et 

d’échanges grâce au salon des exposants et aux séances 

d’affichage. 

• Donner l’occasion aux réseaux de spécialistes en pharmacie 

(RSP) de se réunir et de partager leur savoir-faire.

11 

Program 

Programme 

Saturday, August 11 

Samedi 11 août 

08:30-16:00 CSHP Foundation Fundraising Golf Event 

Tournoi de golf de la Fondation de la SCPH 

15:00-17:30 Registration 

Inscription 

FOX MEADOW GOLF AND COUNTRY CLUB 

DELTA PRINCE EDWARD LOBBY 

17:30-19:00 CHPRB Residency Networking Reception 

Réception de réseautage relatif à la 

résidence du CCRPH 

Delta Prince Edward 

ELFIN/PAKEHA ROOM 

Celebrating its 50th Anniversary 

Spnsored by PPC, 

A Company of the Fresenius Kabi Group 

19:00-21:00 Opening Cocktail Reception 

Cocktail d’accueil 

Sunday, August 12 

Dimanche 12 août 

DELTA PRINCE EDWARD BALLROOM FOYER 

06:00-07:30 5 K Fun Run, 3 K Walk Event 

Course 5 km, promenade 3 km des lève-tôt 


Inscription 



08:15-08:30 Opening Remarks 

Remarques preliminaries 

ISLAND BALLROOM 

08:30-10:00 Plenary Session 

Séance plénière 


Pharmacy Issues and Controversies Forum 

SES 2012 at a Glance 

SÉÉ d’un coup d’oeil 

Educational Sessions 

Séances éducatives 

Sun. Aug. 12 08:30-15:10 • Dimanche 12 août 8 h 30-15 h 10 

Mon. Aug. 13 08:15-15:10 • Lundi 13 août 8 h 15-15 h 10 

Tues. Aug. 14 08:15-12:10 • Mardi 14 août 8 h 15-12 h 10 

Annual General Meeting 

Assemblée générale annuelle 


Registration 

Inscription 

Sat. Aug. 11 15:00-17:30 • Samedi 11 août 15 h-17 h 30 

Sun. Aug. 12 07:30-17:00 • Dimanche 12 août 7 h 30-17 h 

Mon. Aug. 13 07:30-17:00 • Lundi 13 août 7 h 30-17 h 

Tues. Aug. 14 07:30-14:00 • Mardi 14 août 7 h 30-14 h 

Break, Posters 

Pause, Affiches 


Mon. Aug. 13 10:25-10:50 • Lundi 13 août 10 h 25-10 h 50 

Lunch, Exhibitors, Posters 

Déjeuner, Kiosques, Affiches 

Sun. Aug. 12 12:30-14:00 • Dimanche 12 août 12 h 30-14 h 

Mon. Aug. 13 12:30-14:00 • Lundi 13 août 12 h 30-14 h 

Should all Hospital Pharmacists be Residency 

Trained? 

Clarence Chant, PharmD, FCSHP 

Moderator 

St. Michael’s Hospital 

Toronto, ON 

Kent Toombs, BScPhm, ACPR 

Capital Health 

Halifax, NS 

Tania Mysak, BSP, PharmD 


Edmonton, AB 

Moira Wilson, BScPhm 


Saint John, NB 

10:15-10:45 Break, Posters 


PRINCE EDWARD BALLROOM

12 

10:55-11:40 Concurrent Sessions 

Séances concomitantes 

1. The Future Beckons: New Antiviral Agents 

and the Cure for Hepatitis C? 

VALIANT ROOM 

Kathryn Slayter, BScPhm, PharmD, FCSHP 



Halifax, NS 

2. Jump In and Join Us! What’s the CSHP 

2015 Temperature? 

ALEXANDER/CANCEAUX ROOM 

Carolyn Bornstein, BScPhm, ACPR, CGP, 

FCSHP 

CSHP 2015 Project Coordinator 

Newmarket, ON 

3. Biologics in Arthritis: To the Rescue and 

Beyond? 

ELFIN ROOM 

Marie Craig, BScPhm 

Southlake Regional Health Centre 

Newmarket, ON 

11:45-12:30 Concurrent Sessions 

Séances concomitantes 

1. Neuropathic Navigation: Finding our Way 

to Improvements in Pain and Function 

VALIANT ROOM 

Jamie Falk, BScPhm, PharmD 


Winnipeg, MB 

2. Evolution of the Pharmacy Practice Model 

in the RQHR 


Bill Semchuk, MSc, PharmD, FCSHP 


Regina, SK 

3. Warm, Cold, Wet, Dry: An Approach to 

Acute Heart Failure 

ELFIN ROOM 

Sheri Koshman, BScPhm, PharmD, ACPR 

Faculty of Medicine and Dentistry 


Edmonton, AB 

12:30-14:00 Lunch, Exhibitors, Posters 


PRINCE EDWARD BALLROOM 




Making the Case for a National Drug Plan: 

Access, Cost and Health Outcomes 

Marc-André Gagnon, PhD 

School of Public Policy and Administration 

Carleton University 

Ottawa, ON 

15:10-16:40 Annual General Meeting 

Assemblée générale annuelle 


16:40-17:40 Wine & Chat 

Vin et causette 


18:00-24:00 Fun Night 

Partie de plaisir 

Monday, August 13 

Lundi 13 août 


Inscription 

DELTA LOBBY 

08:00-08:15 Announcements 

Annonces 





Ship to Shore: Successfully Navigating 

Transitions in Care 

Neil MacKinnon, BScPhm, MScPhm, PhD, 

FCSHP 

University of Arizona 

Tucson, AZ 

Olavo Fernandes, BScPhm, PharmD, FCSHP 


Toronto, ON

13 

09:35-10:20 Concurrent Sessions & PSN Session 

Séances concomitantes et séance d’un RSP 

1. Palliative Care PSN 

RSP en soins palliatifs 

VALIANT ROOM 

Introduction to Palliative Care 

Carolee Awde-Sadler, BScPhm, RPh, CDE 

Peterborough Regional Health Centre 

Peterborough, ON 

2. Management of Pediatric Asthma: 

A Review and Update 


James Tjon, BSPhm, RPh, PharmD 


Toronto, ON 

3. From Clinician to Pharmacy Leader: 

Capabilities for Effective Leadership 


10:25-10:50 Break, Posters 


10:55-12:25 Workshops 

Ateliers 

Lauza Saulnier, BScPhm, ACPR 


Moncton, NB 


1. A Case-Based Approach to Electrolyte and 

Acid Base Disorders in the Hospitalized 

Patient 

VALIANT ROOM 

Derek Chaudhary, BSc, MHSA, MD, FRCP(C) 



2. Digging into the “Statistical Analysis” 

Section of a Study: A Day at the Beach... 

or Opening Pandora’s Box? 


Scot Simpson, BSP, PharmD, MSc 

Faculty of Pharmacy and Pharmaceutical 

Sciences 


Edmonton, AB 

3. Footprints in the Sand: Steps for 

Successful Career and Life Planning 



FCSHP 


Tucson, AZ 

Audrey Smycniuk, BSc(Hon), BSP, ACPR 


Saskatoon, SK 

12:30-14:00 Lunch, Exhibitors, Posters 






A Hitchhiker’s Ethical Guide through a Drug 

Shortage 

Giles Scofield, JD, MA 

Centre for Clinical Ethics 

Toronto, ON 

A Hitchhiker’s Guide to the Drug Shortage – 

The Clinical Experience 

Don Kuntz, BSP 


Regina, SK 

The Hitchhiker’s Guide to Drug Shortages – 

A Procurement & Inventory Manager’s 

Experience 

Tracy Simpson,BScPhm 


Edmonton, AB 

18:00-24:00 Past Presidents’ Dinner and Dance 

Dîner dansant des anciens présidents 

Tuesday, August 14 

Mardi 14 août 


Inscription 

DELTA LOBBY 

08:00-08:15 Announcements 

Annonces 

ISLAND BALLROOM

14 



09:20-09:50 Break 

Pause 


Patient Advocacy: Making the Case for High 

Cost Medications 

Linda Wilhelm 

Consumer Advisory Council 

Midlands King County, NB 

BALLROOM FOYER 

09:50-10:35 Concurrent Sessions and PSN Session 

Séances concomitantes et séance d'un RSP 

1. What’s New in Breast Cancer Treatment: 

Has Personalized Medicine Come of Age? 

CONSBROOK 

Carlo DeAngelis, BScPhm, PharmD 

Sunnybrook Odette Cancer Centre 

Toronto, ON 

2. Current Advances in Multiple Sclerosis 

VALIANT ROOM 

Mike Namaka, BScPhm, PhD 

Faculty of Pharmacy/Faculty of Medicine 

University of Manitoba 

Winnipeg, MB 

3. Global Health PSN 

RSP en santé mondiale 

GULNARE 

The Benefits of Pharmaceutical 

Management in Tackling Lack of Access to 

Pharmaceuticals in Public Hospitals in 

Kabul, Afghanistan 

Kendall Nicholson 

Health Partners International of Canada 

Dollard-des-Ormeaux, QC 

Vanessa Sherwood, BScPhm, BSc(Hon) 

IWK Health Centre 

Halifax, NS 

2. Digging into the “Statistical Analysis” 

Section of a Study: A Day at the Beach... or 

Opening Pandora’s Box? (encore) 

ELFIN/PEKHEA 


Faculty of Pharmacy and 

Pharmaceutical Sciences 


Edmonton, AB 

3. Joint Surgery/Infectious Disease PSNs 

Séance conjointe des RSP en chirurgie et 

en infectiologie 


Antibiotic Surgical Prophylaxis – is the 

Tide Changing? 

Monique Pitre, BScPhm, FCSHP 


Toronto, ON 

Perioperative Medication Safety: Focus on 

the Operating Room 

Melanie MacInnis, BScPhm, PharmD 

Hamilton Health Sciences Centre 

Hamilton, ON 

12:10 Close of the 65th Summer Educational 

Sessions 

Organized by the CSHP Educational Services 

Committee with assistance from the 2012 Host 

Task Force. 

Clôture des 65 es Séances éducatives d’été de 

la SCPH 

Organisées par le Comité des services éducatifs 

de la SCPH en collaboration avec le Groupe de 

travail hôte des SÉÉ 2012. 

10:40-12:10 Workshops & PSN Sessions 

Ateliers et séances des RSP 

1. Surfing (the Net) or Walking the Beach 

with a Metal Detector? Tips and Tricks to 

Find What You Are Looking For 


Theresa Hurley, BScPhm, ACPR 


Halifax, NS

15 

Speaker Abstracts 

Résumés des conférenciers 

SUNDAY, AUGUST 12 

DIMANCHE 12 AOÛT 

Should All Hospital Pharmacists Have a Residency? 

TANIA MYSAK, BSP, PHARMD, KENT TOOMBS, BSCPHM, ACPR, MOIRA 

WILSON, BSCPHM 

As outlined in CSHP 2015, our profession aims, by 2015, to have 

all new pharmacists entering hospital or related practice 

complete a residency accredited by the Canadian Hospital 

Pharmacy Residency Board. The purpose of this session is to 

debate the merits, or lack thereof, of requiring every hospital 

pharmacist to have a residency at entry to practice in a hospital 

or related healthcare settings. 

There has been a demonstrable shift in the pharmacist’s scope 

of practice from drug preparation and distribution toward direct 

patient care activities. With this continuing trend toward increased 

clinical responsibilities, professional organizations, academia, 

health care systems and other stakeholders have increased their 

expectations with respect to the amount of training required to 

produce an entry level pharmacist. 

Through structured rotations in pharmacy practice, education, 

research and administration, residency programs aim to prepare 

pharmacists for challenging and innovating pharmacy practice. 

Graduate residents are an important source of practitioners and 

many employers list residency training as a preferred qualification 

for clinical practice. 

Controversy does exist as to whether residency training should 

be a mandatory prerequisite for practice. One of the central 

questions in this controversy is whether there is sufficient value 

obtained from completing a residency. There are many 

perspectives on the perceived value from patients, providers, 

employers, payers, society, the profession as a whole and from 

those individuals who have completed residency training. 

Goals and Objectives 

1. To provide different perspectives to either refute or support 

the position that all hospital pharmacists should have a 

residency. 

2. To provide pharmacists with sufficient information to assist 

them to develop an opinion on this issue. 

Self-Assessment Questions 

1. What are the merits of all pharmacists having a residency at 

entry to practice? What are the challenges with achieving this 

goal? 

2. What is the best way to ensure pharmacists have the required 

competencies to deliver direct patient care? 

The Future Beckons: New Antiviral Agents and the 

Cure for Hepatitis C? 

KATHRYN SLAYTER, BSCPHM, PHARMD, FCSHP, CAPITAL HEALTH, 

DALHOUSIE UNIVERSITY, HALIFAX, NS 

In Canada, approximately 250,000 individuals are currently 

infected with Hepatitis C virus (HCV). Every year, approximately 

5000 Canadians, mostly youth, become infected with HCV – 

often during the first year following initiation of injection drug 

use. 

Hepatitis C has rapidly surpassed HIV as a cause of death in the 

US. Roughly three quarters of these deaths occurred in people 

between the ages of 45 and 64. The relatively young age of 

people dying from HCV portends a large and ever-increasing 

health care burden. 

Before 1990, HCV was an incurable, chronic infection and had 

only a 10% cure with early interferon monotherapy. 

Subsequently, therapy for HCV evolved to using pegylated 

interferon and ribavirin. The combination of pegylated interferon 

and ribavirin produces an overall SVR of between 50% and 90% 

depending on the genotype. 

In 2011, the first HCV specific protease inhibitors, boceprevir and 

telaprevir were licensed, after clinical trials showed that these 

drugs combined with pegylated interferon and ribavirin, could 

achieve close to 70% SVR for patients with genotype 1 

infections. 

Treatment of chronic HCV remains complex, however with newer 

therapies we are now able to decrease treatment durations and 

increase cure rates. Currently more than 50 clinical trials are 

evaluating new direct-acting antivirals to treat HCV infection. The 

future holds great promise for newer drugs to improve the 

sustained virologic response, shorten the duration of treatment 

and improve tolerability. 


1. To evaluate the impact of results of clinical trials of approved 

treatment for chronic hepatitis C on current and future patient 

management strategies. 

2. To provide pharmacists the evidence on best practice to 

maximize response and minimize treatment failure in patients 

receiving hepatitis C treatment. 


1. How can pharmacists be better able to provide accurate and 

appropriate counseling as part of the hepatitis C treatment 

team?

16 

2. How can pharmacists integrate practical management 

strategies into the prevention and management of adverse 

effects associated with hepatitis C therapy? 

Jump In and Join Us! What’s the CSHP 2015 

Temperature? 

CAROLYN BORNSTEIN, BSCPHM, ACPR, CGP, FCSHP, CSHP 2015 

PROJECT COORDINATOR, NEWMARKET, ON 

CSHP 2015 is a vision of Pharmacy Practice Excellence. Its 6 

goals aim to ensure that the use of medications is effective, 

evidence-based and safer, and to contribute meaningfully to 

public health. Thirty-six pharmacy practice-related objectives 

support the goals. This session will provide the most up-to-date 

information on the implementation of the CSHP 2015 objectives 

in hospital pharmacy departments in Canada, based on a CSHP 

2015 online survey conducted in March-April 2012. What 2015 

targets have been met or soon will be? What are the top 10 high 

priority objectives of the respondents’ pharmacy departments 

and how do they compare to their current or planned 

implementation? Which objectives are the lowest of lows for 

priority and should we be concerned? Are pharmacists in 

hospitals monitoring AND managing the medication use of 

patients with complex and high risk regimens? Are ambulatory 

patients provided the same services? Is evidence-based practice 

the norm for hospital pharmacists in Canada? Medication 

reconciliation implementation is definitely a priority on admission 

but why not on discharge? Are we reviewing the safety of the 

medication use annually? Are we evaluating our processes for 

compounding sterile products? What about technology? Why 

don’t we see more of it when we know it enhances medication 

safety? Should hospital pharmacies be involved in community 

health initiatives? Do we have emergency preparedness 

programs in place? Results will be compared to the 2009 survey. 

Some of the challenges to pursuing the CSHP 2015 objectives 

will be shared. What’s our biggest obstacle? What resources 

and/or assistance would respondents like CSHP to provide to 

support its members with CSHP 2015? Are the CSHP 2015 tool 

kits helpful and/or being used? Current resources and supports 

for CSHP members will be highlighted. 


1. To provide highlights of the CSHP 2015 progress, or lack 

thereof, to date and share feedback from CSHP members on 

the challenges and barriers to achieving the CSHP 2015 

targets 

2. To highlight some of the many supports, resources and tools 

that CSHP has provided for its members, including future 

plans. 


1. Name 3 of the top 10 high priority CSHP 2015 objectives 

based on the recent 2012 online survey. 

2. Which objectives are considered very low priority according to 

the recent survey? 

3. What are the CSHP 2015 virtual posters and where can they 

be found? 

Biologics in Arthritis: To the Rescue and Beyond? 

MARIE CRAIG, BSCPHM, THE ARTHRITIS PROGRAM, SOUTHLAKE REGIONAL 

HEALTH CENTRE, NEWMARKET, ON 

The purpose of this session is to discuss how the introduction of 

Biologics over a decade ago has changed the landscape of 

Arthritis care. 

This will be presented from the literature, clinical and patient 

perspective. A risk versus benefit treatment model for decision 

making utilized in patient teaching will be shared. The Crystal 

Osteoarthritis Rheumatoid and Enthesopathies (CORE) 

description of Rheumatic Diseases will be provided. The recent 

changes in the understanding of risk of Rheumatic diseases will 

be introduced. The treatment guidelines for Biologic use in 

Rheumatoid Arthritis versus their use in the Spondylarthropathies 

ie Psoriatic Arthritis and Ankylosing Spondylitis will be presented. 

Information from random controlled trials (RCT’s) versus the 

Biologic Registries indicating how Biologics are being used 

clinically will be discussed. The differences in pre-screening and 

the challenges that various biologics present re safety will be 

reviewed. What are the American College of Rheumatology 

(ACR) Guidelines re immunization of patients taking Biologics? 

What does the literature state re holding of Biologics pre-surgery? 

Recent insites re medical problems that also increase TNF and 

which may negatively impact the effectiveness of TNF Alpha 

Inhibitors will be introduced. A Canadian Rheumatology 

Association (CRA) approved website that provides biologic 

patient information will be shared. How can Pharmacists partner 

with hospitalized patients for improved safety and effectiveness? 

What medications are on the horizon that may compete with 

biologics and possibly shift the landscape again? 


1. To evaluate the place in therapy of Biologics in Inflammatory 

Arthritis based on risk versus benefit and practice guidelines 

2. To review the questions and concerns the studies and biologic 

registries present 

3. To discuss how Pharmacists may partner with hospitalized 

Biologic patients for improved safety and effectiveness. 


1. What atypical infections could the hospitalized patient be 

challenged by as a consequence of treatment with a biologic? 

2. What vaccines are classified as “live” that are not 

recommended when a patient is taking a Biologic? 

Neuropathic Navigation: Finding Our Way to 

Improvements in Pain and Function 

JAMIE FALK, BSCPHM, PHARMD, WINNIPEG REGIONAL HEALTH AUTHORITY, 

WINNIPEG, MB

17 

The purpose of this session is to provide an evidence-based look 

at the patient-centred management of neuropathic pain. 

The diagnosis and treatment of neuropathic pain continues to 

develop. Currently however, due to a lack of objectivity in 

assessment, numerous possible pathophysiologies, and the 

myriad of therapeutic options available, many without robust 

evidence and less than ideal adverse event profiles, the 

management pathways of neuropathic pain can be difficult to 

navigate, both for the clinician and the patient. 

In this session we’ll discuss principles that can be utilized as trail 

markers to help us guide our patients toward improved pain and 

functioning. This discussion will include the assessment of the 

patient’s unique neuropathic presentation, the identification and 

translation of risk and benefit likelihoods for pharmacological 

options that are understandable to both the clinician and the 

patient, and therapeutic considerations for more complicated 

individuals such as the elderly and those with multiple 

comorbidities. In addition, this session will explore the 

development of treatment and monitoring plans that involve close 

follow-up, a progressive approach to medication adjustment, and 

a focus on outcomes that are valuable to the patient. 

There are many unanswered questions in the treatment of 

neuropathic pain, but with the use of currently available 

evidence, well-established pharmacotherapeutic principles, and 

sound clinical judgment, the journey toward positive outcomes 

will be less fraught with roadblocks, misdirection, and confusion. 


1. To provide a pharmacological basis for the numerous agents 

currently used in the treatment of neuropathic pain. 

2. To provide an overview of the evidence supporting the various 

agents currently used to manage neuropathic pain, including 

onset, magnitude, and duration of effect on pain and 

functional improvement. 

3. To discuss how utilization of the common adverse event 

profiles of these agents can help tailor medication regimens 

to the individual patient. 

4. To highlight key aspects in the development of a well-defined, 

patient-centred monitoring plan for those with neuropathic 

pain. 


1. What degree of benefit is possible with the first-line agents 

used for treatment of common neuropathic pain conditions? 

2. What agents are reasonable second-line adjunct options for 

treatment of neuropathic pain and how does one decide on 

the appropriate one for the individual patient? 

Evolution of the Pharmacy Practice Model in the 

RQHR 

In 2008, a series of initiatives was begun with a focus on 

redeveloping the pharmacy practice model within the Regina 

Qu’Appelle Health Region. The rationale for this change included 

the concern that we had insufficient pharmacists to meet 

demands for service, the concern that our practice model was 

inconsistent in terms of the care provided from a patient 

perspective, our need to identify what we do for whom, in order 

to best train new members of our team, and the ongoing change 

in the evolution of pharmacy practice including prescriptive 

authority and pharmacist responsibility for outcomes. 

As a result we identified a number of goals that included: 

• Development of a patient-centric model of pharmacist care 

• Provision of clarity and consistency from a patient perspective 

in whom we prioritize for care and the activities we will perform 

• Development of a pharmacy practice model that ensures 

pharmacist job satisfaction by maximizing the patient care role 

of the pharmacist 

• Development of standards of practice that result in maximizing 

the role pharmacists have in direct patient care 

• Development of training tools consistent with standards of 

practice to ensure that new pharmacists are trained to provide 

consistent care to patients 

• Assurance that pharmacist care activities are consistent with 

prescriptive authority and pharmacist responsibility for 

outcomes 

• Development of a series of measures (Key Performance 

Indicators) to ensure that changes are improving the care we 

provide to patients 

• This session will discuss the process, findings and outcomes to 

date in the transition to a New Practice Model. 


The goal of the session is to provide attendees with: 

1. An overview with the rationale and goals of the pharmacist 

practice model change within the RQHR 

2. Insight into the process utilized in the practice model change 

in the RQHR 

3. Results available to date in the practice model redesign in the 

RQHR 


1. Why was it felt that a practice model design was necessary 

within the RQHR? 

2. What were the greatest successes and challenges noted 

within the RQHR process? 

WILLIAM SEMCHUK, MSC, PHARMD, FCSHP, REGINA QU’APPELLE HEALTH 

REGION, REGINA, SK

18 

Warm, Cold, Wet, Dry: An Approach to Acute Heart 

Failure 

SHERI L. KOSHMAN, BSCPHARM, PHARMD, ACPR, DIVISION OF 

CARDIOLOGY, UNIVERSITY OF ALBERTA, EDMONTON, AB 

Heart failure (HF) is a leading cause of both morbidity and 

mortality in Canada. It is estimated that 50% of patients with HF 

will die within 5 years. HF is one of the top reasons for 

hospitalizations and re-hospitalization, resulting in significant costs 

to the healthcare system. 

Acute heart failure, now termed acute heart failure syndrome 

(AHFS) secondary to its varied pathophysiology, etiology and 

clinical presentation, is characterized by new, gradual, or rapid 

worsening of signs and symptoms of HF requiring urgent therapy. 

General management principles include clinical assessment 

(evidence of congestion – wet or dry; evidence of low perfusion 

– warm or cold), identification of etiology and precipitants, 

symptom control and prevention of death. 

Treatment of AHFS is limited secondary to the paucity of clinical 

data of beneficial therapies. Traditional therapies include diuretics, 

vasodilators and inotropes. While these agents have some data 

in terms of symptoms and surrogates, they have limited hard 

clinical outcome data supporting their use. More modern 

therapies include agents such as nesiritide and tolvaptan. These 

agents also have limited data supporting improvement in patient 

outcomes for AHFS. 

Pharmacists play an important role in the management of 

patients with AHFS as well as in the prevention of rehospitalizations. 

Identification and avoidance of precipitants, 

medication teaching and adherence and utilization of evidencebased 

medicines are all areas that pharmacists can improve care 

in this high-risk population. 


1. To overview the pathophysiology of acute heart failure 

syndrome (AHFS) 

2. To described the clinical evaluation of a patient with AHFS 

3. To review pharmacotherapy strategies for the treatment and 

prevention of AHFS 


1. What is the spectrum of clinical presentation in patients 

presenting with AHFS? 

2. What key pharmacotherapeutic strategies are available to treat 

AHFS and what are their impacts on patient outcomes? 

3. What strategies can pharmacist employ to prevent rehospitalizations 

secondary to AHFS? 

Making the Case for a National Drug Plan: Access, 

Cost and Health Outcomes 

MARC-ANDRÉ GAGNON, PHD, ASSISTANT PROFESSOR, SCHOOL OF 

PUBLIC POLICY AND ADMINISTRATION AT CARLETON UNIVERSITY (OTTAWA), 

OTTAWA, ON 

The purpose of this session is to demonstrate that a public and 

universal drug insurance plan covering all prescription drug costs, 

based on first-dollar coverage, is economically possible and 

socially desirable in terms of equity and drug safety. It will also 

demonstrate that, in an appropriate institutional environment, it 

would be the most economically efficient drug insurance plan for 

all Canadians. 

A public drug insurance plan forms an integral part of a country’s 

pharmaceutical policies. The plan must tie together social policies 

designed to provide a minimum of well-being for all citizens, 

health policies designed to optimize public health, industrial 

policies aimed at attracting foreign investment, intellectual 

property policies, as well as tax policies designed to ensure 

greater fairness in redistributing wealth. A drug insurance plan is 

not only a way to compensate for or reimburse drug expenses, 

but also a way to control costs for buyers by giving them 

monopsony bargaining power when dealing with powerful 

transnational pharmaceutical companies. In fact, a drug insurance 

plan that includes a drug assessment process can also help 

distinguish between drug products in order to ensure the quality, 

safety and cost-effectiveness of prescription drugs. The 

complexity of these various aspects of pharmacare must be 

considered in order to determine the best drug insurance plan to 

meet the common goals of a community. 

The main argument that is typically made against the 

establishment of universal Pharmacare is economic in nature. 

The presentation explains that a universal drug plan providing 

first-dollar coverage, established alongside a rigorous drug 

assessment process, would not only ensure greater fairness in 

accessing medication and improve drug safety, but would also 

help contain the inflationary costs of drugs. The economic 

argument in favour of such a program is loud and clear, since 

Canadians could save between 10% and 42%—up to $10.7 

billion—of total drug expenditures, while improving access and 

health outcomes. 

After presenting the most important issues about access to 

medications and cost-containment, the presentation will explore 

different scenarios for implementing a national drug plan, based 

on how we would want to use the drug plan to serve purposes 

of innovation policy in the pharmaceutical sector. 


1. To provide an understanding of the many roles and functions 

of Pharmacare in a community. 

2. To provide an in-depth analysis of the flaws in the current 

blend of existing public and private drug plans.

19 

3. To analyze how a universal Pharmacare could help improve 

access to medicines and health outcomes, while reducing 

costs. 

2. What are the purposes that would serve universal Pharmacare 

and why would it be a more efficient system in economic 

terms? 


1. What are the main flaws in the current blend of existing public 

and private drug plans? 

MONDAY, AUGUST 13 

LUNDI 13 AOÛT 

Ship to Shore: Successfully Navigating Transitions in 

Care 

NEIL J. MACKINNON, BSCPHM, MSCPHM, PHD, FCSHP, UNIVERSITY OF 

ARIZONA, TUCSON, AZ, OLAVO FERNANDES BSCPHM, ACPR, PHARMD, 

FCSHP, UNIVERSITY HEALTH NETWORK/LESLIE DAN FACULTY OF PHARMACY, 

UNIVERSITY OF TORONTO, TORONTO, ON 

The goal of this session is to provide pharmacists with the latest 

evidence and tips and strategies to foster the safe and effective 

transition of care for patients in the medication-use system. As the 

evidence from the literature readily shows, transitions in care can 

be risky vulnerable moments for many patients. In fact, one could 

argue that transitions of care provide a great opportunity for 

improving patient outcomes and thus should be a primary focus 

of hospital pharmacy activities. In addition, evidence has emerged 

in recent years about which practical strategies can be employed 

by hospital pharmacists and other members of the healthcare 

team to help patients successfully navigate these potentially 

hazardous transition points. The presenters will summarize 

studies from the perspective of patients, physicians, and 

pharmacists while reviewing the latest in concepts from seamless 

care to medication reconciliation to hospital admissions. 

Attendees will leave the session with new insights and practical 

strategies on how to help their patients. 


1. To provide pharmacists with the highlights of recently 

published studies on transitions in care. 

2. To empower pharmacists to improve the safety and 

effectiveness of transition points in care in their own practice 

setting. 


1. What are the various levels of intensity of medication 

reconciliation and how effective are these levels at affecting 

patient-level outcomes? 

2. Which ‘specific individual interventions’ or ‘bundles of 

interventions’ can reduce 30-day patient re-admissions ? 

3. Do I incorporate the patient’s perception on transitions of care 

in my own practice setting? 

4. How can I apply the lessons learned from these studies to 

improve patient safety in my own practice setting? 

Introduction to Palliative Care 

CAROLEE AWDE-SADLER, BSCPHM, RPH, CDE, PETERBOROUGH REGIONAL 

HEALTH CENTRE, PETERBOROUGH, ON 

This presentation is for practitioners new to palliative care practice. 

It will review general principles of care, the mechanism of 

symptom development, and the drug classes used in their 

management. Non drug measures and the importance of a team 

approach will be included. Quantifying symptoms and targeting 

drug therapy by drug mechanism of action to the mechanism of 

the pathophysiology will be emphasized. Pain, nausea, vomiting, 

mental status changes and hypercalcemia will be covered. There 

will be discussion of care at end-stage including conversion of 

medication routes and holistic care of the patient and family. 

Goal and Objectives 

1. To provide practitioners with a philosophical framework for 

Palliative Care 

2. To provide pharmacists new to palliative care with a basic 

understanding of the demands of the practice 

3. To encourage team based care of the patient and family 

4. To identify the Palliative Care PSN as a resource 


1. What are the next steps if the narcotic dose is not maintaining 

pain management? 

2. What can the pharmacist do to alleviate suffering? 

Management of Pediatric Asthma: A Review and 

Update 

JAMES TJON, BSPHM, PHARMD, HOSPITAL FOR SICK CHILDREN, TORONTO, 

ON 

Asthma is the most common chronic respiratory disease in 

Canada. It is estimated that asthma affects up to 300 million 

people worldwide. In the United States, despite advances in 

management, pediatric asthma continues to be a primary cause 

of visits to the emergency department, hospitalizations and school 

days missed. 

In 2010, the Canadian Thoracic Society (CTS) Asthma Committee 

published an Asthma Management Consensus Summary for

20 

children six years of age and older and adults. This summary 

included an updated management continuum, which was 

adapted from the 2003 Canadian guidelines, the Global Initiative 

for Asthma guidelines, the British Thoracic Society and Scottish 

Intercollegiate Guidelines Network Guidelines, the National 

Institutes of Health National Heart, Lung and Blood Institute 

Expert Panel Report 3 and new literature. The first evidence-based 

update to this clinical practice guideline was provided in early 

2012, aimed at the management of preschoolers, children and 

adults. The purpose of the update is to address controversial 

topics and/or gaps in the guidelines. 

Pharmacotherapy for pediatric asthma includes reliever (shortacting 

beta2-agonists, anti-cholinergics, systemic corticosteroids) 

and controller therapy (inhaled corticosteroids, long-acting beta2- 

agonists, combination therapy, leukotriene receptor antagonists, 

anti-immunoglobulin, theophylline). With the recent increasing 

evidence in the literature, the management of pediatric asthma 

has become more defined. With the complexities and challenges 

faced in management, pharmacists have a pivotal and unique 

role in educating children and their families about this disease 

and the medications involved. 


1. To discuss the appropriate treatment and maintenance therapy 

of the child with an acute exacerbation of asthma 

2. To provide pharmacists with an overview of the CTS’s Asthma 

Consensus Summary and update to the guidelines 


1. What are the recent 2012 updates to the CTS Asthma 

Guidelines for management in children and how will they 

affect your practice? 

2. Is there a role for magnesium in treating children with acute 

asthma? 

From Clinician to Pharmacy Leader: Capabilities for 

Effective Leadership 

LAUZA SAULNIER, BSCPHM, ACPR, HORIZON HEALTH NETWORK, MONCTON, 

NB 

Several reports have highlighted the need for major reform in the 

Canadian health care system. Change is expected and is part of 

the natural growth of any dynamic and healthy organization. 

Leaders and decision-makers, middle managers and front-line 

health care providers throughout the system must be engaged in 

the visioning, creation and implementation of concepts, initiatives 

and measures to improve the health care system and its 

sustainability. 

Effective leadership is critical to successfully transform our 

systems. A focus on leadership development is required to 

strengthen leadership capacity and support ongoing recruitment 

and retention initiatives for the profession. Using the LEADS in a 

Caring Environment framework, essential capabilities in leading 

change in the Canadian health care system will be reviewed. 


1. To gain a broader understanding of leadership capabilities 

required to improve the performance of our health systems. 

2. To encourage talent development and build capacity in 

pharmacy leaders. 


1. What are the capabilities I would like to focus on to lead more 

effectively? 

2. What actions can I integrate into my daily practice to 

strengthen my leadership abilities? 

A Case-Based Approach to Electrolyte and Acid Base 

Disorders in the Hospitalized Patient 

DEREK NAVEEN CHAUDHARY, BSC(HON), MHSA, MD, FRCP(C), QUEEN 

ELIZABETH HOSPITAL, CHARLOTTETOWN, PEI 

It is well established that electrolyte and acid base abnormalities 

are prevalent in hospitalized patients. The purpose of this session 

is to provide the attendee with some basic knowledge as it 

pertains to normal and abnormal water and sodium physiology. A 

case-based approach will also be used to illustrate the workup of 

a patient with hyponatremia / hypernatremia. Emphasis will be 

placed on the adverse consequences of improper treatment. 

The second part of the workshop will also use a case-based 

approach outlining the basic steps to evaluate a patient with an 

acid base perturbation. 


1. Understand basic water and sodium physiology 

2. Understand abnormalities of water and sodium physiology as 

it pertains to hyponatremia and hypernatremia 

3. Understand the importance of proper treatment in patients 

with hyponatremia and hypernatremia 

4. Understand simple acid base abnormalities encountered in 

hospitalized patients 


1. Can I evaluate a patient with hyponatremia or hypernatremia? 

2. How do I avoid potential fatal mistakes in treating a patient 

with hyponatremia or hypernatremia? 

3. Do I have a general approach to approaching a patient with an 

acid base disturbance? 

Digging into the “Statistical Analysis” Section of a 

Study: A Day at the Beach… or Opening Pandora’s 

Box? 

SCOT H. SIMPSON, BSP, PHARMD, MSC, ASSOCIATE PROFESSOR, FACULTY 

OF PHARMACY & PHARMACEUTICAL SCIENCES, UNIVERSITY OF ALBERTA, 

EDMONTON, AB

21 

A fundamental part of quantitative research is to select the most 

appropriate statistic for testing the hypothesis. Whether you are an 

investigator helping to design the project or a clinician critically 

appraising the final report, we all need to know how to determine 

which statistic to use. 

This workshop will use the following approach to achieve the goal 

and objectives. First, the facilitator will provide a short overview of 

general categories and terms used in statistics. This presentation 

will introduce the key issues to consider when selecting a 

statistical test as well as a flowchart to help facilitate selection. 

Second, a research question will be used to discuss possible 

hypothesis, variables to use, and selection of an appropriate 

statistical test. Participants will work in small groups to discuss 

these issues and then share comments with the larger group. 

Third, a recent publication examining the research question will 

be used to illustrate how to critically review the “data analysis” 

section. 


1. The purpose of this workshop is to describe a practical 

approach for selecting a statistical test. 

2. Identify the critical pieces of information needed to help 

determine what statistical test would be appropriate. 

3. Review the underlying assumptions of common statistical tests 

used in pharmacy practice research. 

4. Increase confidence and understanding when critically 

reviewing the “data analysis” or “statistical analysis” paragraph 

of a paper. 


1. What are 3 critical pieces of information that I need to help 

select an appropriate statistical test? 

2. What is the difference between parametric and non-parametric 

statistics? 

3. When should I ask for advice from a biostatistician? 

Footprints in the Sand: Steps for Successful Career 

and Life Planning 

NEIL J. MACKINNON, BSCPHM, MSCPHM, PHD, FCSHP, UNIVERSITY OF 

ARIZONA, TUCSON, AZ, AUDREY J. SMYCNIUK, BSC(HON), BSP, ACPR, LEO 

PHARMA INC., REGINA QU’APPELLE HEALTH REGION, SK 

The goal of this session is to provide pharmacists of all ages and 

experience – from students, residents, new practitioners to mid 

and late career pharmacists – with the opportunity to creatively 

and carefully consider the development of a career and life plan. 

In this interactive workshop, the workshop facilitators will: (1) 

review literature on job satisfaction and pharmacists including a 

discussion of key implications for hospital pharmacists and career 

planning, (2) guide the participants in their own self-assessment 

of values, needs, interests and abilities, (3) describe the principles 

of goal setting, and (4) review the key elements of creating a life 

plan. In addition, the workshop facilitators will describe the 

indispensable qualities of a leader and how pharmacists can strive 

to develop these qualities. Participants will leave the workshop 

with new insights into the career and life planning process and 

will have the opportunity to think about their own career 

expectations. Participants are encouraged to bring their 

smartphones for interactive, real-time texting-based questions. 


1. To provide pharmacists with the highlights of published studies 

into job satisfaction and pharmacists. 

2. To empower pharmacists with tools to create their own career 

and life plans. 


1. What are my most desired qualities in a hospital pharmacy 

workplace? 

2. Do I have any personal shortcomings that can impede me 

from achieving my career choice to the maximum and, if so, 

how do I address them? 

3. What are the key aspects of my own life plan? 

A Hitchhiker’s Ethical Guide through a Drug Shortage 

GILES SCOFIELD, JD, MA, CENTRE FOR CLINICAL ETHICS, TORONTO, ON 

The purpose of this presentation is to describe some of the ways 

in which ethics helps and enables others to understand and think 

through some of the issues raised the drug shortage crisis. 

Basically, the drug shortage crisis brings questions about resource 

allocation to the forefront. It is a situation in which rationing scarce 

resources takes on real meaning. 

Pragmatically understood, a seemingly unmanageable situation 

becomes more manageable if one thinks concretely about what 

is on hand, what can be substituted, what can be used more 

conservatively, what can be saved, and what can be shared. 

Because one must always connect substantive issues to process 

concerns, it is also important to maintain clear, open, and – for 

lack of a better word – democratic lines of communication. 

That said, it is important to bear in mind that what begins as a 

crisis can, depending on how things unfold, turn into a 

catastrophic situation, in which case the ethical analysis becomes 

radically different, because decisions will be made according to 

what resembles a war-time triage model. Because rationing health 

care resources appropriately pre-supposes that we know how to 

discriminate among everyone who is in need without 

discriminating against anyone who is in need, we need to be 

honest---with ourselves and with others---about the true nature of 

the choices that confront us and about the fact that it is we who 

are making them. 


1. To describe approaches to health care rationing that aspire to 

be both pragmatic and democratic in nature.

22 

2. To describe how the concept of ‘tragic choices’ can and should 

inform our approach to such situations. 


1. What is A4R? 

2. What is a tragic choice? 

A Hitchhiker’s Guide to the Drug Shortage – 

The Clinical Experience 

DON KUNTZ, BSP, REGINA QU’APPELLE HEALTH REGION, REGINA, 

SASKATCHEWAN 

The purpose of this session is to highlight some of the effects 

drug shortages have on patients in acute and long term care and 

the impact of pharmacy services in being able to respond with 

effective communications and treatment alternatives. 

Drug shortages are occurring in Canada and abroad for a variety 

of reasons including raw material shortages and quality control 

issues, leading to voluntary production withdrawal of some 

pharmaceuticals and increased production times for others. 

Healthcare providers are responsible for ensuring patients receive 

the most appropriate and timely drug therapy. Clinical pharmacists 

have the responsibility of ensuring supply availability, validity of 

indication for the drug, dosing, dosage form and duration of 

therapy. They have been invaluable in communicating the drug 

shortage issues and ensuring where supply is limited, that it is 

utilized for the most appropriate patients. Clinical pharmacists can 

provide drug information regarding interchangeable brand 

availability, product substitution, reduced dosages and dosage 

titration to effect and monitor for outcomes. 


1. To provide pharmacists with examples of communication and 

front line experiences for optimal drug therapy in times of drug 

shortages. 

2. To describe how such times provide pharmacists with the 

opportunity to renew evidence based practice standards and 

reapply protocols and procedures developed but too often 

forgotten. 


1. What common sense clinical interventions can be applied to 

patient care regarding drug shortages? 

2. What resources do hospital pharmacists have to assist with 

timely, evidence based, safe and effective decision making as 

we work through the reality of drug shortages? 

The Hitchhiker’s Guide to Drug Shortages – A 

Procurement & Inventory Manager’s Experience 

Tracey Simpson BScPhm, Alberta Health Services, Edmonton, AB 

The purpose of this session is to describe the various contributing 

factors leading to drug shortages. As well, to describe the process 

utilized in Alberta Health Services to manage drug shortages. The 

number of drug shortages has been increasing over the past few 

years, especially the number of critical drug shortages. Hospitals 

have had to develop processes to manage drug shortages and 

communicate the potential therapeutic alternatives to the 

clinicians and front-line staff. Managing drug shortages is very 

work-intensive and involves many different 

disciplines/departments. With the scope of the recent injectable 

drug shortages, hospitals across Canada have had to source 

additional resources to manage the supply disruption and finetune 

their drug shortage management processes. 


1. To provide information on the contributing factors leading to 

drug shortages. 

2. To describe the Alberta Health Services process for managing 

drug shortages. 


1. What are some of the contributing factors leading to drug 

shortages? 

2. Are there aspects of the drug shortage management process 

used in Alberta Health Services that other hospitals in Canada 

could adopt? 

TUESDAY, AUGUST 14 

MARDI 14 AOÛT 

Patient Advocacy: Making the Case for High Cost 

Medications 

LINDA WILHELM, PATIENT ADVOCATE, MIDLAND, KINGS COUNTY, NB 

Despite the arrival of inovative new treatments in the past 

decade, untreated Rheumatoid Arthritis (RA) remains a major 

concern. One quarter of men and women between the ages of 

twenty-five and fourty-four are not in the labour force due to 

arthritis, resulting in significant cost to the healthcare system and 

to society overall. RA is a misunderstood condition with the 

seriousness being under acknowledged by health care 

professionals, governments and even patients themselves. 

The condition is commonly treated with analgesics, non-steroidal 

anti-inflammatory drugs, disease modifying anti-rheumatic drugs 

and corticosteroids. Many patients are non-responsive to these 

drugs and quickly reach the end of their treatment options.

23 

The new biologic drugs are very expensive, the first of these was 

approved in 2000 to treat RA. All provinces and insurance 

companies have now listed biologics for RA on their formularies, 

with specific criteria that older, less expensive treatments have 

failed to adequately control the disease. Gaps in coverage still 

exist across the country, as do significant delays in diagnosing 

and treating RA resulting in unnecessary costs to the healthcare 

system and disability. 


1. It is cost effective for specific patients to be able to access 

very costly medications, providing a set criteria is in place and 

they have failed to achieve adequate disease control with 

older, less expensive treatments. 

2. In order for patients to be able to access expensive 

medications, we must advocate to government to educate 

them about our disease. 


1. How have patients, through their advocacy efforts improved 

access to high cost medictions? 

2. How has the advocacy improved health outcomes for all RA 

patients? 

Current Advances in Multiple Sclerosis 

MIKE NAMAKA, BSCPHM, MSCPHM, PHD, MSMED. CA, ASSOCIATE 

PROFESSOR, NEUROSCIENTIST AND NEUROLOGY CLINICIAN, UNIVERSITY OF 

MANITOBA, FACULTY OF PHARMACY AND MEDICINE, WINNIPEG, MB 


At the end of this section, you will be able to: 

• Understand what constitutes the diagnosis of multiple sclerosis 

(MS). 

• Identify the classification of the various types of MS. 

• Describe the pathophysiology involved in MS. 

• Describe the diagnostic tests used to diagnose and treat MS. 

• Describe the clinical presentations of MS. 

• Understand the current treatment strategies for MS. 

Define Terms: 

• Multiple Sclerosis (MS) 

• Relapse 

• Relapsing Remitting MS 

• Secondary Progressive MS 

• Primary Progressive MS 

• Progressive Relapsing MS 

• Clinically Isolated Syndrome 

• Optic Neuritis 

• Autoimmune disease 

• Inflammatory Cytokines 

• Th 1 & Th 2 cells 

• Antigen presenting cells (macrophages, monocytes and 

dendritic cells) 

• Antigen 

• Adhesion Molecules (ICAM-1; VCAM-1) 

• Oligodendrocytes 

• Myelin 

• Lesions 

• Blood brain barrier 

• Central nervous system myelin proteins (MBP, PLP,MAG, MOG) 

The Benefits of Pharmaceutical Management in 

Tackling Lack of Access to Pharmaceuticals in Public 

Hospitals in Kabul, Afghanistan 

KENDALL NICHOLSON, MSC, INTERNATIONAL DEVELOPMENT, HEALTH 

PARTNERS INTERNATIONAL OF CANADA, DOLLARD-DES-ORMEAUX, QC 

Health Partners International of Canada (HPIC) is a humanitarian 

not-for-profit relief and development organization dedicated to 

improving access to medicine and enhancing health in the 

developing world. HPIC contributes to well-being by providing 

donations of essential medicines, supplies and vaccines, building 

national health sector capacities and responding to emergencies 

and health threats. 

HPIC is currently implementing the Capacity Building and Access 

to Medicines (CBAM) Project in Afghanistan, in which the goal is 

to support the Ministry of Public Health (MoPH) of Afghanistan 

to effectively ensure greater and more equitable access to priority 

pharmaceuticals and medical supplies for all Afghans, with a 

specific emphasis on women and children. HPIC is partnering 

with the Afghan MoPH to concentrate on five specific areas in 

efforts to build the capacity of the national government and to 

improve access to vital pharmaceuticals and medical supplies for 

the population. 

One of the five project areas where HPIC is supporting the 

Afghan government is in sending medicine donations, solicited 

from Canadian pharmaceutical companies, to Kabul public 

hospitals. In addition to the medicine donations, HPIC is also 

assisting hospital pharmacists in implementing pharmaceutical 

management tools in order to better manage and account for 

the medicines begin received and distributed to patients. 

Through medicine donations and improved management 

systems at hospital pharmacies, HPIC is working to increase 

access to medicines for the Afghan population. 


1. To describe the HPIC Capacity Building and Access to 

Medicines Project in Afghanistan and the current project 

advances being made at Kabul public hospital pharmacies. 

2. To provide Canadian pharmacists with an example of the type 

of development work being done in pharmacies in the 

developing world. 

Self-Assessment Questions

24 

1. What are the five elements of the CBAM project and what 

type of activities is HPIC currently undertaking at the Kabul 

public hospital pharmacies? 

2. How is HPIC working with pharmacists in Kabul, Afghanistan 

to increase access to medicines for the population? 

Surfing (the Net) or Walking the Beach with a Metal 

Detector? Tips and Tricks to Find What You Are 

Looking For 

THERESA HURLEY, BSCPHM, ACPR, CAPITAL HEALTH, HALIFAX, NS, 

VANESSA SHERWOOD, BSC(HONS) PHARMACY, IWK HEALTH CENTRE, 

HALIFAX, NS 

Drug Information is a specialized area of pharmacy concerned 

with the provision of unbiased, well referenced, and critically 

evaluated information on a variety of aspects of pharmacy 

practice. In reality, many questions that arise on a day-to-day 

basis are challenging to answer as there may be sparse 

information. Hospital pharmacists may work in a centre that has 

a Drug Information service or have access to a regional service. 

However, even in centres with Drug Information pharmacists 

there are many occasions where pharmacists are required to 

answer drug information questions without additional assistance. 

This session will be a workshop-style, case-based format looking 

at a variety of drug information questions including the 

specialized populations of pregnancy, lactation, psychiatry, 

pediatrics and palliative care. Real life examples from the Drug 

Information centres in Halifax will be used and the session will 

include an opportunity to ask general questions of the Drug 

Information pharmacists. Web-based resources as well as 

traditional texts will be used to highlight the usefulness of 

different resources in answering particular questions, and there 

will be an assessment of the strengths and weaknesses of 

individual resources. 

While one short session cannot possibly attempt to answer all 

drug information questions hospital pharmacists encounter, this 

session will provide participants with some tips and tricks to 

answer some challenging questions effectively and quickly. 


1. Educate pharmacists on resources available to answer drug 

information questions 

2. Encourage discussion and questions on the best approach to 

drug information questions 

3. Raise awareness of specific resources for specialized 

populations 

Self-Assessment Questions: 

1. Which websites/texts will I use to answer drug information 

questions after this session? 

2. What are the weaknesses of these resources and how can I 

address these? 

Digging into the “Statistical Analysis” Section of a 

Study: A Day at the Beach … or Opening Pandora’s 

Box? 

SCOT H. SIMPSON, BSP, PHARMD, MSC, ASSOCIATE PROFESSOR, FACULTY 

OF PHARMACY & PHARMACEUTICAL SCIENCES, UNIVERSITY OF ALBERTA, 

EDMONTON, AB 

A fundamental part of quantitative research is to select the most 

appropriate statistic for testing the hypothesis. Whether you are 

an investigator helping to design the project or a clinician critically 

appraising the final report, we all need to know how to 

determine which statistic to use. 

This workshop will use the following approach to achieve the 

goal and objectives. First, the facilitator will provide a short 

overview of general categories and terms used in statistics. This 

presentation will introduce the key issues to consider when 

selecting a statistical test as well as a flowchart to help facilitate 

selection. Second, a research question will be used to discuss 

possible hypothesis, variables to use, and selection of an 

appropriate statistical test. Participants will work in small groups 

to discuss these issues and then share comments with the larger 

group. Third, a recent publication examining the research 

question will be used to illustrate how to critically review the 

“data analysis” section. 


1. The purpose of this workshop is to describe a practical 

approach for selecting a statistical test. 

2. Identify the critical pieces of information needed to help 

determine what statistical test would be appropriate. 

3. Review the underlying assumptions of common statistical 

tests used in pharmacy practice research. 

4. Increase confidence and understanding when critically 

reviewing the “data analysis” or “statistical analysis” paragraph 

of a paper. 


1. What are 3 critical pieces of information that I need to help 

select an appropriate statistical test? 

2. What is the difference between parametric and nonparametric 

statistics? 

3. When should I ask for advice from a biostatistician? 

Antibiotic Surgical Prophylaxis – is the Tide 

Changing? 

MONIQUE PITRE, BSCPHM, FCSHP, UNIVERSITY HEALTH NETWORK, 

TORONTO, ON 

It is estimated that 15% of patients undergoing a surgical 

procedure will have a surgical site infection. This can have a 

negative effect on mortality, readmission rates, length of hospital 

stay and cost. The purpose of this session is to review the

25 

evidence and rationale for antimicrobial surgical prophylaxis and 

opportunities to improve practices. 


1. To review the appropriate use of prophylactic antibiotics 

2. To identify the key parameters for optimal antimicrobial 

surgical prophylaxis including dose, timing and duration 

3. To review the potential negative impact of prophylactic 

antibiotics 

4. To review the role of antiseptic prophylaxis 


1. How do you determine the most appropriate agent for the 

surgical procedure? 

2. What is the optimum timing of antibiotic administration? 

3. Is there any benefit to administering antibiotic prophylaxis 

beyond 24 hours? 

Perioperative Medication Safety: Focus on the 

Operating Room 

MELANIE MACINNIS, BSCPHM, PHARMD, HAMILTON HEALTH SCIENCES, 

HAMILTON, ON 

The purpose of this session is to provide the attendee with an 

understanding of the inherent medication safety risks present in 

the operating room (OR) to patients and staff on a daily basis. 

The OR is an area of the hospital which requires many high-alert 

medications to be present in order for anesthesia to be 

administered and surgeries to proceed. Despite the knowledge 

of the easy accessibility and availability of agents such as 

narcotics, neuromuscular blocking agents, and vasoactive 

medications; the systems developed around medication use in 

this environment still rely heavily on individual accountabilities 

and low leverage safety strategies. 

The pharmacist’s role within perioperative care tends to focus on 

pre-operative clinic screenings; post-operative care unit 

involvement; and medication reconciliation activities. Pharmacy 

technicians may or may not be utilized within the operating 

rooms to manage medication distribution and storage. 

Pharmaceutical products are delivered to operating rooms; but 

there tends to be a “black hole” beyond the main OR doors 

where there is little understanding of medication use. Pharmacist 

involvement in the operating room; and increased understanding 

of anesthesia, surgical, and nursing practices in the operating 

room environment can lead to safer medication use, distribution, 

and storage. 

This presentation will review literature on medication safety 

occurrences within the operating rooms; and specifically 

anesthesia practice. The experience of one large tertiary care 

teaching center will also be shared; including risk assessment in 

the operating rooms; evaluation of automated medication 

dispensing technology for the operating room; and results of an 

failure mode effect analysis (FMEA). 


1. To review the literature on the incidence and cause of 

medication safety occurrences in the operating room 

environment; and specifically anesthesia practice. 

2. To review pressures and risks in the OR with respect to safety 

of patients and staff and legislative requirements. 

3. To review the role of automated anesthesia carts as one 

potential strategy to minimize the risk of medication safety 

occurrences. 

4. To highlight the successes and challenges of one institution 

attempting to provide a safer operating room environment for 

patients and staff. 


1. What is my institutions model of medication distribution and 

storage in the OR for ward stock medications and for 

narcotics? 

2. Are there any changes which can be implemented at my 

institution which decrease the reliance on low leverage error 

reduction strategies?

26 

Upcoming Events 

Événements à venir 

Professional Practice Conference (PPC) 2013 

February 2-6, 2013 

Sheraton Centre Toronto Hotel 

Toronto, ON 


February 1-5, 2014 


Toronto, ON 


January 31 to February 5, 2015 


Toronto, ON 


January 30 to February 3, 2016 


Toronto, ON 

Summer Educational Sessions (SES) 2013 

August 10-13, 2013 

Hyatt Regency Calgary 

Calgary, AB 


August 9-12, 2014 

Delta St. John’s Hotel & St John’s Convention Centre 

St. John’s, NL 


August 8-11, 2015 

Hilton London Ontario 

London, ON 

Attendance at CSHP conferences, PPC and SES, are 

approximately 700 and 250 respectively, excluding exhibitors. 

Please note we offer an exhibit program at both venues. 

For further information, please contact 

Desarae Davidson, CSHP National Office 

T: (613) 736-9733, Ext. 229 

F: (613) 736-5660 

E: ddavidson@cshp.ca 

Poster Sessions 

Séances d’affichage 

2 CSHP 

Targeting Excellence 

in Pharmacy Practice 

CSHP 2015 is a quality program that sets out a vision of 

pharmacy practice excellence in the year 2015. Through this 

project, CSHP challenges hospital pharmacists to reach 

measurable targets for 36 objectives grouped under 6 goals, all 

aimed toward the effective, scientific, and safe use of 

medications and meaningful contributions to public health. 

CSHP 2015 applies to inpatients and outpatients, community 

and hospital pharmacists, and all practice settings. Posters identified with a “CSHP 

2015” logo are those judged by the CSHP 2015 Steering Committee to be 

particularly relevant to one or more of the 36 objectives. 

2 SCPH 

Point de mire 

sur l’excellence en 

pratique pharmaceutique 

Le projet SCPH 2015 est un programme axé sur la qualité qui 

propose une vision de l’excellence en pratique 

pharmaceutique en l’an 2015. Au moyen de ce projet, la SCPH 

met les pharmaciens d’établissements au défi d’atteindre les 

cibles mesurables de 36 objectifs répartis entre 6 buts, visant 

tous l’utilisation efficace, scientifique et sûre des médicaments 

ainsi que des contributions significatives à la santé publique. Le 

projet SCPH 2015 s’applique aux patients hospitalisés et externes, aux 

pharmaciens d’hôpitaux et communautaires, et à tous les milieux de pratique. Les 

affiches marquées du logo « SCPH 2015 » sont celles que le comité directeur du 

projet SCPH 2015 a jugé particulièrement appropriées à l’un ou l’autre des 36 

objectifs. 

Sunday, August 12, 2012 Viewing • Affichage: 10:15-10:45 

Dimanche 12 Août Presentation • Présentations: 12:30-14:00 

1. An Evaluation of Inpatient Diabetes Care management among Non-Critically Ill 

Patients in the General Internal Medicine Unit at a large Canadian Teaching 

Hospital 

2. The Cost-Impact of Using patient’s Own Multi-Dose Medications in Hospitals 

3. Integration and Evaluation of Pharmacists on the Acute Resuscitation Team 

4. Rural Telepharmacy – Implementation on a Provincial Scale 

5. Enhancing Customer Satisfaction with Pharmacy Services in a Province-Wide 

Healthcare Organization 

6. Evaluation of a Fall Risk Tool Including Medication Use 

7. Development, Delivery and Assessment of an Interactive Infectious Disease 

Educational Series for Pharmacists 

8. Identification of Hospital Pharmacists’ Learning Needs 

9. Development of a Regional Database of Pharmacy-Based Research and 

Quality Improvement Projects 

Monday, August 13, 2012 Viewing • Affichage: 10:25-10:50 

Lundi 13 Août Presentation • Présentations: 12:30-14:00 

1. A Single-Centre Experience of Voriconazole Therapeutic Drug Monitoring in the 

Management of Leukemia/Bone Marrow Transplant Patients 

2. What Patients Want: Preferences Regarding Hospital Pharmacy Services 

3. Benchmarking Sedative Hypnotic Drug use in Nova Scotia Hospitals 

4. Evaluation of Medication Turnaround Time Following Implementation of Digital 

Fax Technology for Prescriber Order Transmission to Pharmacy in a Tertiary 

Care Hospital 

5. Conversion of Dialysis Patients from Epoeitin Alfa to Darbepoietin Alfa is Cost- 

Saving in a Community Hospital Setting 

6. Examining Trends in the Administration of “As Needed” Medications to 

Inpatients with Behavioural and Psychological Symptoms of Dementia 

7. Everything Including the Lipid Sink: Emergency Department Use of Intravenous 

Lipid Emulsion for Amitriptyline Overdose 

8. Characterization of Renal Dysfunction in a Cohort of Adult HIV-Infected 

Patients: A Retrospective, Observational Case-Control Study

27 

Sunday, August 12, 2012 

Dimanche 12 Août 

An Evaluation of Inpatient Diabetes Care Management 

among Non-Critically Ill Patients in the General Internal 

Medicine Unit at a Large Canadian Teaching Hospital 

ANDREW F. W. HADDY, MICHAEL WONG, JIN-HYEUN HUH, BOHDAN J. LALUCK JR., TORONTO 

WESTERN HOSPITAL, UNIVERSITY HEALTH NETWORK, TORONTO, ON 

Rationale: Poor management of inpatient hyperglycemia is associated with an 

increased risk of morbidity, mortality, length of hospital stay, and admission rate to 

the intensive care unit. For these reasons the American Diabetes Association, 

American Association of Endocrinologists and Society of Hospital Medicine 

recommend a fasting blood glucose target

28 

provided for project management and technology; pharmacy staff were reassigned 

to this project. Pharmacy project staff provided all training to site-based Pharmacy 

staff. 

The first 37 sites were installed in March 2012; remaining sites will be in place by 

August 2012. 

Evaluation: Phase one installation was completed within timelines. A preimplementation 

survey captured perceptions of current dispensing systems. 

Table 1: 

Medication Dispensing Systems Baseline Survey Results (n=128) 

Satisfied with current medication dispensing system 65% 

Dispensing activity impacts my other responsibilities 83% 

I am always able to work to full scope of practice 12% 

I am always able to maintain service levels (53% always/often) 19% 

My site has used RNs to provide med verification 29% 

Availability of telepharmacy would have improved dispensing time in 39% 

instances when no onsite Pharmacy staff were available 

Availability of telepharmacy would have improved dispensing safety in 41% 

instances when no onsite Pharmacy staff were available 

I have traveled to cover staffing shortages at other sites 27% 

Dispensing delays due to need for staff to travel have occurred 16% 

A second survey assessed satisfaction with phase one installation processes. 

Table 2: 

Phase I installation feedback survey (n=34 of 105, 32%) 

I have used the Telepharmacy webpage 49% 

There are space issues at my site with the equipment 57% 

I have used some aspect UC on a daily basis 

19% daily 

27% never 

I have used the document camera 30% 

Telepharmacy supports the ability to work according to standards 

of practice 

The enhanced access of peers to me is beneficial 

I understand how telepharmacy could benefit me 

43% agree 

50% agree 

76% agree 

I understand how telepharmacy could benefit Pharmacy 73% 

department 

I would have preferred to be trained in person 24% 

Ratings for acceptability of the document camera 

Ratings for acceptability of headsets/speakers 

4-8% poor 

3-11% poor 

Importance: Advantages include: inter-site support for continuity of services 

despite onsite staff absences; optimized scope of practice (technician checking, 

pharmacist direct patient care); multi-site educational opportunities; and 

decreased travel for working groups. 

Enhancing Customer Satisfaction with Pharmacy 

Services in a Province-Wide Healthcare Organization 

IAN CREURER, EXECUTIVE DIRECTOR, PRACTICE DEVELOPMENT AND INTEGRATION*JEREMY 

SLOBODAN, DIRECTOR, THERAPEUTICS AND CLINICAL PRACTICE**PHARMACY SERVICES, ALBERTA 

HEALTH SERVICES 

Rationale: To assess customer satisfaction, Pharmacy Services conducted focus 

groups with nursing staff at sites across the province. 

An improvement initiative was selected to be applicable to all organizational 

settings. This was challenging, as Alberta Health Services (AHS) consists of 

117,000 employees, with 103 acute and mental health hospitals and services 

offered at 400 facilities across Alberta. 

Improving awareness and access to drug information resources was selected as 

the improvement initiative. 

Description of Program: A presentation for delivery by pharmacy staff to 

nursing staff was developed, describing use of online resources, the AHS 

Pharmacy Drug Information Service, and the role of pharmacy staff in providing 

drug information. 

A toolkit made it easier for front line pharmacy staff to organize and deliver 

presentations to their nursing colleagues. 

Steps Taken: A staff group developed the presentation and toolkit. Toolkit items 

included an introductory letter to the nursing unit/site manager, tips on organizing 

sessions, speaker notes, sign up and evaluation forms, and handouts for 

attendees. 

Success depended on pharmacy staff taking onus to deliver the presentation to 

their nursing colleagues. AHS Pharmacy Leadership was engaged to promote to 

Pharmacy staff and to disseminate the toolkit; several site staff groups 

incorporated this initiative into their local Pharmacy Awareness Week activities. 

Evaluation 

Table 1: 

Nursing Focus Group feedback – Themes 

Session activity: 

26 Focus group sessions at 18 hospital sites, with participation from 165 nursing 

staff 

Themes identified: 

• Increase Pharmacy Hours/ Staffing 

• Improve Medication Dispensing 

• Improve Process of Returning Medications to Pharmacy 

• Improve Medication Ordering 

• Improve Medication Storage/ Stocking at Unit 

• Improve Medication Labelling 

• Improve Communication 

• Improve Medication Information (online and Pharmacist-provided) 

• Increase Pharmacists’ involvement with Patient Care 

• Improve Electronic Systems 

Table 2: 

Evaluation of “Improving Access to Drug Information” sessions 

Survey results 

Question 

“Yes” responses 

The duration of the training session was appropriate 99.7% 

I know more about which drug information resources 99.3% 

are available 

I now know better how to find the online drug 

information resources 

I am more likely to use the online drug information 

resources now 

I am more likely to use the AHS Drug Information 

Service now 

Importance 

99.3% 

98.9% 

98.0% 

The handout was helpful 98.6% 

I would like presentations on other topics 37.9% 

Presentation demographics 

Date range June 2011-March 2012 

• Presentations 102 

• Sites participating 48 

• Nurses participating 1121 

Survey responses (rate) 767 (68%) 

This addressed a nurse- identified need, to support better patient care. In addition, 

interaction and dialogue was promoted between front line pharmacy and nursing 

staff.

29 

Evaluation of a Fall Risk Tool Including Medication Use 

LISA CURRIE 1 , KATHERINE GIANNOULIS 2 , INGRID SKETRIS 1 , GORDON FLOWERDEW 1 , PATRICIA 

BILSKI 2 , KATHY MACPHERSON 1 AND GRAEME BETHUNE 2 

1 DALHOUSIE UNIVERSITY, HALIFAX, NS 

2 CAPITAL DISTRICT HEALTH AUTHORITY, HALIFAX, NS 

Rationale: Falls cause significant morbidity and mortality in the elderly and 

medications contribute to falls risk. Various tools have been used to assess risk. 

The Veterans’ Memorial Building (VMB) a long-term care facility in Halifax uses the 

Fall Risk Tool (FRT) (adapted from Oak Brook Healthcare Centre) which assesses 

8 domains including medications. 

Objectives: To examine the association between the Fall Risk Tool including 

medication use and falls in residents at the VMB. 

Methods: All individuals admitted to the VMB within a 16-month period (January 

2009-April 2010) (N=132) and who had a FRT completed were assessed 

(N=76). Electronic incidence charts provided fall occurrence data. Drug use was 

obtained from pharmacy dispensary records. Drugs were assigned WHO- 

Anatomical Therapeutic Chemical 2012 codes and classified by fall risk category 

determined by literature. Descriptive statistics, Kaplan-Meier curves and 

proportional hazards analysis were used to determine if the FRT score and drug 

use were predictive of subsequent falls. 

Results: 76 patients had an FRT completed. FRT scores ranged from 2-20 with a 

mean value of 11.51 (SD 4.19). Most residents (59.2%) demonstrated a low risk 

with a score between 0-12 and did not have a documented fall occurrence 

(59.21%). 97.5% of patients were prescribed at least one high risk medication. Of 

the 3207 drugs prescribed a high proportion (66.9%) were classified as low risk 

medications. Of all medications prescribed, the most frequently prescribed class of 

high risk medication was narcotics (5.5%). 

Conclusion: Most VMB residents (97.5%) received at least 1 high risk 

medication associated with falls. Pharmacists should be familiar with falls risk 

assessment tools. A high score on the medication domain may serve as a useful 

prompt for a medication review. Work is needed to determine how to improve 

early assessment of fall risk and to decrease fall occurrences via implementation of 

prevention strategies. 

Development, Delivery and Assessment of an 

Interactive Infectious Disease Educational Series for 

Pharmacists 

C. DUCLOS; R. LAW, ST. MICHAEL’S HOSPITAL, TORONTO, ON 

Rationale: The framework for our antimicrobial stewardship program 

emphasizes that all clinicians are responsible for antimicrobial stewardship, and 

identifies education as a core component of ASP. To support our pharmacists in 

being stewards, the Infectious Disease (ID) Educational Series for Pharmacists was 

developed, implemented and assessed. 

Description: Topics including interpreting and utilizing antibiograms, 

antimicrobial de-escalation, antimicrobial pharmacokinetics and 

pharmacodynamics, intravenous to oral conversion of antimicrobials were 

presented in 13 bi-monthly sessions. Content included foundational ID knowledge 

and specific examples of how to optimize antimicrobial therapy. Presentations 

were designed around a game show format to engage the audience and provide 

opportunities for participants to solve case-based questions. Participants 

completed a three question pre- and post-test to assess content knowledge as 

well as a presentation evaluation, which utilized a 5-point scale to assess content, 

delivery, and visuals and materials. 

Evaluation: A total of 14.5 hours of content was delivered with an average of 18 

(range 12 to 23) participants attending each session. The percentage of 

participants who had a perfect score in the post-test was 68% compared to 40% 

in the pre-test (p < .0001), suggesting an increase in ID knowledge. All 

respondents rated content, delivery, and visuals and materials in the range of 

‘acceptable’ to ‘excellent’, with a median score (out of 5) of 5 for content, 5 for 

delivery and 4 for visuals and materials. Based on the written comments, the 

content and format of the presentations were positively received and topics 

covered were useful for practice. 

Conclusion: The interactive ID educational series was well-received by 

participants and enhanced pharmacists’ ID/antimicrobial stewardship knowledge 

to support their role as antimicrobial stewards. 

Identification of Hospital Pharmacists’ Learning Needs 

STACEY MACAULAY, HORIZON HEALTH NETWORK, MONCTON, NB, JENNIFER RYAN, HORIZON 

HEALTH NETWORK, SAINT JOHN, NB, DOUGLAS DOUCETTE, HORIZON HEALTH NETWORK, 

MONCTON, NB 

Rationale: In 2008, New Brunswick Department of Health reorganized from 8 

to 2 regional health authorities (RHAs). One of these 2 resulting RHAs, Horizon 

Health Network, is now the largest health authority in Atlantic Canada and 

currently employs 102 pharmacists. There is substantial variation among these 

pharmacists’ practice sites, their educational degrees and speciality training, and 

their percentage of time spent in direct patient care, centralized services, and 

research and education activities. Therefore, a survey was conducted to identify 

the learning needs of this diverse group of pharmacists, for the purpose of 

influencing the development of a 3-year education plan. 

Objectives: The primary objective of this survey was to identify the learning 

needs of pharmacists at Horizon Health Network. The secondary objective was to 

determine the preferred characteristics of continuing education sessions. 

Methods: The study population was all pharmacists employed at Horizon Health 

Network. The survey was administered electronically and contained the categories 

of demographics, patient care, teaching, research, therapeutics, CSHP 2015, 

pharmacist prescribing, and characteristics of continuing education sessions. 

Results: The response rate was 77.5%. Evidence-based practice, teaching skills, 

and research skills were the main learning needs identified regarding skill 

development. The therapeutic topics that were most commonly identified as 

learning needs were anticoagulation and infectious diseases. Learning needs 

related to pharmacist prescribing included: 1) ordering and interpreting lab tests; 

2) performing therapeutic drug monitoring; and 3) implementing a 

communication system to notify physicians of pharmacists’ involvement. Out of 

the 10 CSHP 2015 objectives addressed in the survey, there was only 1 for which 

≥50% of pharmacists felt either highly or very highly prepared. The preferred 

frequency for continuing education sessions was once monthly, with case 

presentations being the preferred format. 

Conclusion: Pharmacists identified a wide variety of learning needs relating to 

skill development and knowledge advancement. 

2 CSHP 



Development of a Regional Database of 

Pharmacy-Based Research and Quality 

Improvement Projects 

STACEY MACAULAY, HORIZON HEALTH NETWORK, MONCTON, NB, JENNIFER RYAN, HORIZON 

HEALTH NETWORK, SAINT JOHN, NB, DOUGLAS DOUCETTE, HORIZON HEALTH NETWORK, 

MONCTON, NB 

Rationale: In 2008, New Brunswick Department of Health reorganized from 8 to 

2 regional health authorities (RHAs). One of these 2 resulting RHAs, Horizon 

Health Network, is now the largest health authority in Atlantic Canada and 

employs 102 pharmacists and 159 pharmacy technicians. Given the large size of 

this pharmacy team, a mechanism was needed to track ongoing projects. 

Therefore, a survey was conducted to identify recent and ongoing pharmacybased 

research and quality improvement projects being undertaken throughout 

the RHA. A database of these projects was then developed. 

Objectives: The primary objective of this survey was to identify pharmacy-based 

research and quality improvement projects completed within the last 5 years at 

Horizon Health Network, for incorporation into a regional database. 

Methods: The study population was all pharmacists and pharmacy technicians 

employed at Horizon Health Network. They were contacted via email and asked to 

complete a questionnaire. The questionnaire sought to obtain general information 

about the project, members of the research team, project status (i.e. complete/ 

incomplete), research funding, and posters or oral presentations completed. 

Results: A total of 61 projects was submitted, 48 of which were classified as 

research projects and 13 of which were quality improvement projects. The most 

common study design was a prospective cohort study. Medication/patient safety 

was the most common focus of the projects, followed by the value/role of a 

pharmacist. The database was developed using Microsoft Access and will be 

updated periodically. Anticipated uses of the database include assisting with 

preparing reports for management teams, identifying research themes and 

resource gaps, identifying staff members involved with research, assisting with 

project timeline management, and facilitating collaboration among staff. 

Conclusion: A regional database was successfully developed which contains 

searchable information on numerous research and quality improvement projects 

conducted within Horizon Health Network within the past 5 years.

30 

Monday, August 13, 2012 

Lundi 13 Août 

A Single-Center Experience of Voriconazole Therapeutic 

Drug Monitoring (TDM) in the Management of 

Leukemia/Bone Marrow Transplant (L/BMT) Patients 

JANICE YEUNG 1 , YU-CHEN LIN 1 , DAILIN LI 2 , MORRIS PUDEK 2 , DIANE ROSCOE 2 , CARMEN 

MOUNTFORD 1 , TRANA HUSSAINI 1 , MARYSE POWER 3 , RAEWYN BROADY 3 

1 CSU PHARMACEUTICAL SCIENCES, (VANCOUVER, CA); 

2 PATHOLOGY & LABORATORY SCIENCES, (VANCOUVER, CA); 3LEUKEMIA/BMT PROGRAM OF 

BC (VANCOUVER, CA) 

Background: Voriconazole is frequently used in the prevention and treatment of 

fungal infections in immunocompromised patients. Non-linear pharmacokinetics 

and wide inter- and intrapatient variability lead to unpredictable plasma 

concentrations. Studies demonstrate that voriconazole trough levels correlate with 

efficacy and toxicity and it is proposed that TDM may improve patient outcomes. A 

6-month pilot project was initiated to evaluate the appropriateness and ordering 

and sampling practices of voriconazole TDM in our patients. 

Methods: All TDM episodes performed from May 1 to November 30, 2011 at 

the L/BMT Program of British Columbia were included. Voriconazole was 

measured by UPLC using a UV detector. Steady-state voriconazole trough levels 

were defined as the following: undetectable (less than 0.3mg/L); well below 

therapeutic range (0.3 - 0.7mg/L); borderline therapeutic (0.8 – 0.9mg/L); 

therapeutic (1 - 5.5mg/L); toxic (greater than 5.5mg/L). 

Results: 59 patients were included and 290 levels were performed. Initial 

voriconazole concentrations were non-therapeutic in 26/59 patients: 2 

undetectable, 12 well-below therapeutic, 5 borderline therapeutic and 7 toxic. Of 

these 26 patients, only 6 had their dosage adjusted and 20 did not. Reasons for 

non-action included inappropriately drawn levels, not at steady-state, prophylaxis, 

desire to wait for a repeat level or no reason was given at all. Of those 6 patients 

where an action was taken, 3 became therapeutic, 1 borderline therapeutic and 2 

did not have follow-up levels. 

Conclusion: This pilot study highlights the importance of appropriate TDM 

sampling and interpretation. 26/59 (44%) patients had initial voriconazole levels 

that were not therapeutic and only 6 of those patients had their voriconazole 

dosing adjusted. On the basis of these findings, we conclude that voriconazole 

TDM should be implemented to optimize patient outcomes and that there is a 

need for a standardized dosing adjustment algorithm to assist clinicians in 

interpreting and adjusting dosing for voriconazole trough levels. 

2 CSHP 


What Patients Want: Preferences Regarding 

Hospital Pharmacy Services 


DOUGLAS DOUCETTE, REGIONAL PHARMACY SERVICES, HORIZON HEALTH 

NETWORK, NEW BRUNSWICK; PAULA BUCKLEY AND ODETTE GOULD, DEPARTMENT OF 

PSYCHOLOGY, MOUNT ALLISON UNIVERSITY, SACKVILLE, NB 

Rationale: The role of hospital pharmacists has evolved over the past couple 

decades from medication preparation and distribution to active involvement in 

health teams as clinicians who identify and resolve patients’ medication-related 

issues in an effort to improve patient outcomes. As part of a phone survey to 

determine the baseline prevalence of patients who recall interacting with the 

pharmacist during their hospital admission (CSHP 2015 Objective 1.5), we also 

asked about their preferences for pharmacy services provided. 

Objectives: To analyse content of open-ended survey responses to the question 

asked of patients recently discharged from hospital. 

Methods: A telephone questionnaire was completed by 400 former inpatients 

randomly selected following discharge from acute care hospitals. Responses were 

recorded to the question “what service or information would you like a pharmacist 

to provide in the hospital that would most help you in managing your 

medications?” Two raters established response categories and independently 

scored the survey responses. Inter-rater agreement was measured for number of 

items present in a participant’s response (segmentation) and how to categorize 

each item identified (content categorization). 

Results: Three global categories of responses were obtained, with each having 

multiple sub-categories: Information about Medication; Self-Disclosure, and 

Pharmacy Services. Almost half of all responses (n=192) were related to general 

information about medication, e.g. list, purpose, new meds. Other frequently used 

sub-categories were Self-Disclosures (n=142; experience with pharmacy, 

medication or hospital) and Medication Cautions (n=139; side effects, 

interactions, allergies). Responses were less frequently under sub-categories of 

Adherence (n=67), Services (specific to Pharmacy, n=49), or Information Source 

(regarding medications, n=36). Total agreement rate for segmenting was 92.49% 

and for content categorization was 85.86%. 

Conclusions: Most patients would like a hospital pharmacist to provide a 

general medication overview, including information about side effects and 

interactions, during their admission. A future study may assess patients’ willingness 

to select from a guiding list of potential clinical services. 

Benchmarking Sedative-Hypnotic Drug Use in Nova 

Scotia Hospitals 

BOWLES S 1 , NEVILLE H 1 , DAGENAIS J 2 

1 CAPITAL HEALTH PHARMACY DEPARTMENT, HALIFAX, NS; 

2 UNIVERSITY OF TORONTO, TORONTO, ON 

Rationale: The use of sedative-hypnotic drugs (SHD) is associated with falls in 

the elderly which can lead to disability, hospitalization, and death. The use of SHD 

in Nova Scotia (NS) hospitals is unknown. 

Objectives: To evaluate the magnitude and type of SHD used in nine provincial 

district health authorities. 

Study Design and Methods: This was a retrospective evaluation of SHD use 

(benzodiazepines, chloral hydrate, trazodone and zopiclone) for the years 2009- 

2011 in adult hospitals. Hospital purchasing data was obtained from the NS 

Provincial Drug Distribution Program. Data was converted to defined daily doses 

(DDD) and divided by 100 patient-days for each hospital. Hospitals were grouped 

by district and by size and median use analyzed using the Kruskal-Wallis test. 

Pharmacy directors were provided with confidential reports to benchmark their 

district against the provincial rate. 

Results: Eight of 15 SHDs accounted for 96% of total use. The overall provincial 

rate was 51.7 DDD/100 patient-days; individual district rates ranged from 34.3 – 

61.8. There was no significant difference in median use among the nine districts 

(p=0.16). The most frequently used SHDs were zopiclone (15.4 DDD/100 

patient-days), lorazepam (14.3), and diazepam (8.6). No differences in use of 

SHDs were observed based on hospital size. Pharmacy directors found the 

benchmarking method to be useful and thought that having the information 

would improve the quality and safety of patient care. 

Conclusion: Benchmarking sedative-hypnotic drug use can be a useful indicator 

of overall use, identifies the most common SHDs, and provides preliminary data to 

support more in-depth analysis of the appropriate use of SHDs in NS hospitals. 

Other institutions can compare their own usage against the NS standardized rate. 

Evaluation of Medication Turnaround Time Following 

Implementation of Digital Fax Technology for Prescriber 

Order Transmission to Pharmacy in a Tertiary Care 

Hospital 

NODWELL L 1 , NEVILLE H 1 , ALSHARIF S2 

1 CAPITAL HEALTH, HALIFAX NS; 

2 DALHOUSIE UNIVERSITY, HALIFAX NS

31 

Rationale: Reducing medication turnaround time in hospitals can improve 

efficiency, patient safety and quality of care. Scanning Digital Physician Order 

Technology (SDPOT), which scans physician orders by nursing staff and sends 

them digitally to the pharmacy for verification and processing, was implemented to 

reduce turnaround time. 

Objectives: To evaluate medication turnaround time before and after 

implementation of SDPOT for all medications and antibiotics only. 

Study Design and Methods: This was a retrospective evaluation of the time 

between physician composition and pharmacy verification of orders (Phase 1) 

and the time between physician composition to nurse administration of the 

medication to the patient (Total). Medication orders were audited during June 6- 

10, 2011 (before) and September 26-30, 2011 (after) for three hospital sites. 

Included orders were composed while the pharmacy was open, composed and 

administered on the same day, new orders or an increase in dose, frequency or 

change in route. For medication order sets, only the first order was included. 

Prescriptions that were PRN (as needed), self-administered, or chemotherapy 

were excluded. Median turnaround times were analyzed in SPSS using the Mann- 

Whitney U test. 

Results: There were 356 orders and 304 orders audited before and after SDPOT 

implementation, respectively. The primary reason for excluding orders was lack of 

a prescriber composition time. The median turnaround time for Phase 1 for all 

medications was 2h 13 min before SDPOT, which significantly decreased to 1 h 

45 min after SDPOT (p=0.03). Total turnaround time also significantly decreased 

from 5 h 29 min to 4 h 59 min for all medications (p=0.04). There were no 

differences in turnaround times for antibiotics. 

Conclusion: Implementation of SDPOT was associated with a decreased 

medication turnaround time of 30 minutes. Other health information technology 

solutions, such as computerized physician order entry, should be explored to 

further decrease turnaround times. 

Conversion of Dialysis Patients from Epoeitin Alfa to 

Darbepoietin Alfa is Cost-Saving in a Community 

Hospital Setting 

AWDE-SADLER C., RPH 1 , KIRKWOOD J., RN CNEPH(C) 1 , BEAUBIEN E., MD 1 

1 PETERBOROUGH REGIONAL HEALTH CENTRE; PETERBOROUGH, ON 

Rationale: Erythropoiesis-stimulating agents (ESA), epoetin alfa (EPO) and 

darbepoetin alfa (DPO), manage anemia in hemodialysis (HD) patients. 

Objectives: To compare patient stability and the cost of EPO vs. DPO in a 

community HD clinic. 

Methods: Patients at the Peterborough Regional Health Centre (PRHC) were 

switched from EPO to DPO according to the dose conversion ratio (DCR) used at 

a teaching hospital (The Ottawa Hospital). Individual doses were adjusted to 

maintain patients’ target hemoglobin (Hb). All patients for whom data were 

available on the ESA dose for one month before and 6 months after the switch 

were included in this retrospective study. Weekly doses of ESA, and monthly Hb, 

ferritin, and transferrin saturation (TSat) were recorded. Paired sample signed rank 

tests were performed. 

Results: The mean age of patients (n=50) was 71 years. Median weekly doses 

of EPO and DPO were 8000IU and 28mcg, respectively [median DCR = 286]. 

Mean Hb and ferritin remained stable with the switch from EPO to DPO [Hb: 114 

and 111g/L (p=0.0538); ferritin: 497 and 521mcg/L (p=0.29), respectively]. 

There was a small drop in the mean TSat from 31% to 24% (p=0.0001). 

Assuming list prices of $0.01425/IU EPO and $2.68/mcg DPO, the average costs 

of ESA per patient were $114 and $75, respectively. An average of 

$39/week/patient was saved with DPO. With over 200 patients treated annually, 

>$405,600 could be saved each year at the PRHC. 

Conclusion: This “real-world” cost-effectiveness evaluation of community 

hospital HD patients switched from EPO to DPO showed the potential for 

significant cost-savings without negatively impacting target anemia parameters. The 

results were consistent with those previously reported from larger teaching centres 

despite the more elderly population in this community setting indicating that an 

EPO:DPO DCR > 200 and substantial ESA cost savings may be achieved in most 

HD settings. 

Examining Trends in the Administration of “As Needed” 

Medications to Inpatients with Behavioural and 

Psychological Symptoms of Dementia 

ROBERT NEUMANN, CENTENNIAL CENTRE FOR MENTAL HEALTH AND BRAIN INJURY, PONOKA, AB, 

PETER FARIS, FOOTHILL MEDICAL CENTRE, CALGARY, AB, JANISE PROUDFOOT, CENTENNIAL 

CENTRE FOR MENTAL HEALTH AND BRAIN INJURY, PONOKA, AB 

Rationale: The use of chemical restraint on a “pro re nata” (PRN) basis is utilized 

in patients suffering from behavioural and psychological symptoms of dementia 

(BPSD), but may lead to double dosing and adverse effects. 

Objectives: To identify individuals who were predisposed to PRN administration 

and at which times PRN restraint was more likely to be administered. 

Methods: Chart reviews were completed on patients who had a diagnosis of 

dementia from May 1, 2009 until April 30, 2011. Medication administration 

records were reviewed for PRN use of medications prescribed for aggression, 

agitation, or insomnia (antipsychotics, benzodiazepines, antidepressants, mood 

stabilizers, zopiclone). Data collected included age, sex, time of day, and day of 

week of administration. Poisson regression models were used to model 

associations between factors of interest and rates of PRN use. 

Results: A total of 170 individuals with dementia were included; 49% were 

males and 42% of patients were 65-79 years. Over a total of 49221 bed days 

3958 PRNs were administered. Rates of PRN use were over twice as high in 

patients =80 years (rate ratio [RR]: 

2.26; 95% Confidence Interval [CI] = 1.21-4.24). Also, rates of PRN 

administration were higher between 1600-1700 (RR = 2.94; 95% CI = 2.44- 

3.74) and 0000-0100 (RR = 2.57; 95% CI = 2.04-3.22) compared to average 

rates. Weekends had a 21% higher rate of administration compared to weekdays 

(95% CI: 17%-26%). 

Conclusions: Younger individuals with dementia were more likely to receive 

PRN medications for BPSD. In addition, PRNs were more likely to be administered 

on weekends, and at particular times during the day. Sundowning, staff shift 

change and administration in lieu of adequate staffing may explain some of the 

differences in rates of administration, but further research is needed to evaluate 

the outcomes associated with increased use. 

Everything Including the Lipid Sink: Emergency 

Department Use of Intravenous Lipid Emulsion for 

Amitriptyline Overdose 

SALLY GINSON DUKE, LESLIE MANUEL, HORIZON HEALTH NETWORK, THE MONCTON HOSPITAL, 

MONCTON, NB 

Rationale: Existing acute management guidelines for tricyclic antidepressant 

overdose do not include intravenous lipid emulsion (ILE) as a standard 

intervention. References suggest to consider ILE use in the event of refractory 

hypotension or dysrhythmias. 

Description of Case: A 50 year old male arrived unresponsive at the 

emergency department. Electrocardiogram (ECG) reflected a wide complex 

tachycardia and a tricyclic overdose was suspected. A pharmacy fax confirmed 

amitriptyline 25mg x 200 tablets had been filled on the date of presentation and 

this was believed to be the only medication ingested. Cardiac arrest ensued and 

generalized seizure activity observed. Sodium bicarbonate boluses and infusion 

were initiated in addition to fluid resuscitation, dopamine and norepinephrine 

intravenous (IV) infusions, and single IV doses of midazolam and phenytoin. 

Despite these measures, recorded blood pressure (BP) averaged 70/39 with 

widened QRS complex intermittently noted via ECG. Decision made to administer 

ILE 20% at dose of 100ml IV over 1 minute then 400ml IV over 30 minutes. 

Minutes after ILE administration, BP increased to 85/50. Four hours following ILE, 

the dopamine infusion was stopped and norepinephrine weaned to a 

maintenance rate. Patient remained hemodynamically stable thereafter. 

Evaluation of Literature: The use of ILE is a relatively new intervention in the 

management of tricyclic overdose. At least 6 published case reports in adults and 

1 published case report in a toddler describe ILE use as beneficial in significant 

overdoses of tricyclic antidepressants. 

Importance of Case to Pharmacy Practitioners: Sharing this case will add 

to the current literature describing use of ILE, the benefit of which may outweigh 

any risk in a tricyclic overdose not responding to conventional treatment.

32 

Emergency departments should stock the 500ml bags of 20% lipid emulsion with 

other antidotes in an easily accessible location. 

Characterization of Renal Dysfunction in a Cohort of 

Adult HIV- Infected Patients: A Retrospective, 

Observational Case-Control Study 

M MACNEIL 1 , B LYNN JOHNSTON 2,3 , P POYAH 2,4 , D HAASE 2,3 , K THOMPSON 2 , K SLAYTER 1,2,3 

1 DEPARTMENT OF PHARMACY CAPITAL DISTRICT HEALTH AUTHORITY (CDHA) HALIFAX, NS; 

2 DEPARTMENT OF MEDICINE, DALHOUSIE UNIVERSITY; 

3 DIVISION OF INFECTIOUS DISEASES CDHA; 

4 DIVISION OF NEPHROLOGY CDHA 

Rationale: The incidence and prevalence of kidney disease are rising among 

HIV-infected individuals. Limited knowledge is available on how to best identify 

and then subsequently manage those patients deemed to be at risk for renal 

dysfunction or damage. 

Objectives: The primary objective of our study was to identify risk factors for 

renal dysfunction and/or renal damage. Our secondary objective was to develop a 

tool that could identify and manage those HIV-infected patients at increased risk 

for renal dysfunction. 

Study Design and Methods: This was a retrospective, observational, casecontrol 

study comparing HIV-infected patients with renal dysfunction and/or 

damage to those without dysfunction/damage. Renal dysfunction was defined as 

a Glomerular Filtration Rate (GFR) < 60 ml/min. Renal damage was defined as 

the presence of microalbuminuria. Chi square tests and subsequent multivariate 

analysis were used to analyze relationships between study groups. 

Results: 72-patients with renal dysfunction and/or damage were compared to 

105 controls. Factors shown to be associated with renal dysfunction and/or 

damage included the use of non-antiretroviral medications (55.6% vs. 34.3%, P = 

0.0050); hypertension (43.1% vs. 20%, P = 0.0009), moderate-to-severe liver 

disease (4.2% vs. 0%, P = 0.0656), diabetes (with or without end-organ damage 

(6.9% vs. 1%, P = 0.0415; 15.3% vs. 3.8%, P = 0.0071)), and nadir CD4 cell 

count (182 vs. 220, P = 0.0769). After multivariate analysis, hypertension (OR = 

2.28; p = 0.0332) remained as an independent risk factor for renal dysfunction or 

damage. 

Conclusions: Our study demonstrates the impact that chronic disease states 

have on the risk for developing renal dysfunction and/or renal damage in patients 

infected with HIV. A tool for identifying and managing patients with early signs of 

renal dysfunction was developed that stresses the importance of both chronic 

disease management and the appropriate monitoring of potentially nephrotoxic 

medications. 

Poster Abstract Reviewers Sincere appreciation is extended to the following abstract reviewers for SES 2012. 

Réviseurs des résumés d’affiches Avec tous nos remerciements aux réviseurs des résumés pour les SÉÉ 2012. 

Educational Services Committee 

Comité des services éducatifs 

Erica Wang 

Trudy Arbo 

Elaine Chong 

Toni Bailie 

Alison Callaghan 

Roxane Carr 

Clarence Chant (adjudicator) 

Research Committee 

Comité de recherche 

Sheryl Zelenitsky 

Marc Perreault 

Sal Kanji 

Sheri Koshman 

Roxane Carr 

Dawn Dalen (adjudicator)

33 

Call for Abstracts 

2013 Professional Practice Conference (PPC) 

Sheraton Centre Toronto Hotel, Toronto, Ontario 

February 2 to 6, 2013 

GENERAL INFORMATION 

Category 

Author must specify the category that best suits the particular 

abstract. 

1. Original Research (includes Pharmaceutical/Basic, 

Science/Clinical Research, Drug Use Evaluations, Systematic 

Reviews and Meta-Analysis, Pharmacoeconomics Analysis, etc.) 

2. Case Reports 

3. Pharmacy Practice (includes Administration Projects, Health 

Professional Education, Medication Safety Initiatives, etc.) 

CSHP 2015 

CSHP 2015 related abstracts will be designated as such at PPC. If 

your abstract is linked to CSHP 2015 initiatives, please clearly 

indicate this on the online abstract submission form. 

Abstract Submissions 

All abstract submissions must be submitted no later than 1800h 

(Eastern Daylight Time) on October 7, 2012. 

Abstracts MUST be submitted electronically. Please complete the 

abstract submission form online at CSHP’s Web site 

(http://www.cshp.ca) prior to submitting the abstract. If you are 

submitting more than one abstract, an abstract submission form 

must be completed for each abstract. Abstracts are then 

submitted by e-mail to ddavidson@cshp.ca. Please provide 2 

copies of your abstract. One copy must be blinded (remove 

authors’ affiliations and any identifying features in body of 

abstract). Please indicate in the filename which copy is blinded. 

Please submit your file in MS Word Format. 

Note that for PPC 2013, a small number of abstracts will be 

selected by the Research Committee to be presented as brief 

oral presentations. Please indicate whether you are interested in 

having your poster considered for an oral presentation on the 

abstract submission form. 

Abstract review and grading is conducted by 2 randomly 

assigned, blinded, and independent reviewers. Abstracts are 

selected on the basis of scientific merit, originality, level of 

interest to pharmacists, and compliance with style rules. 

Guidance for authors and sample abstracts will be available on 

the CSHP website shortly at www.cshp.ca/event/PPC2013. 

Demande de résumés 

Conférence sur la pratique professionnelle 2013 (CPP) 

Hôtel Sheraton Centre, Toronto (Ontario) 

Du 2 au 6 février 2013 

RENSEIGNEMENTS GÉNÉRAUX 

Catégorie 

L’auteur doit indiquer la catégorie qui sied le mieux au résumé 

soumis. 

1. Recherche initiale (inclut la recherche pharmaceutique ou 

fondamentale, scientifique ou clinique, les évaluations de 

l’utilisation des médicaments, les examens systématiques et 

les méta-analyses, les analyses pharmacoéconomiques, etc.) 

2. Observations cliniques 

3. Pratique pharmaceutique (inclut les projets administratifs, la 

formation des professionnels de la santé, les projets liés à la 

sécurité des médicaments, etc.) 

SCPH 2015 

Les résumés liés au projet SCPH 2015 seront désignés comme 

tels sur les lieux de la CPP. Si votre résumé est relié au projet 

SCPH 2015, assurez-vous de le mentionner clairement sur le 

formulaire de soumission en ligne des résumés. 

Soumission des résumés 

Tous les résumés doivent être soumis au plus tard à 18 h (heure 

avancée de l’est) le 7 octobre 2012. 

Les résumés DOIVENT être présentés électroniquement. Veuillez 

remplir le formulaire de soumission en ligne des résumés affiché 

sur le site Web de la SCPH à (http://www.cshp.ca) avant de 

soumettre votre résumé. Si vous présentez plus d’un résumé, 

vous devez remplir un formulaire pour chaque résumé soumis. 

Les résumés sont ensuite expédiés par courriel à 

ddavidson@cshp.ca. Veuillez fournir deux exemplaires de votre 

résumé. Un de ces exemplaires doit être anonyme. (Il faut 

supprimer du corps du texte l’affiliation des auteurs et les 

éléments qui révèlent leur identité.) Le nom du fichier doit 

préciser quel exemplaire est anonyme. Le fichier doit être 

présenté en format MS Word. 

Notez que pour la CPP 2013, quelques résumés seront choisis 

par le comité de recherche afin d’être présentés sous la forme 

de brefs exposés oraux. Veuillez indiquer votre intérêt à ce que 

votre résumé soit considéré pour présentation orale sur le 

formulaire de soumission. 

Les résumés sont examinés et évalués par deux réviseurs 

indépendants assignés au hasard et en aveugle. Les résumés 

seront choisis en tenant compte de leur valeur scientifique, leur

34 

Failure to comply with requirements for submission, including 

submission of blinded abstract or any other style rules will result 

in automatic rejection of the submission. 

Research in progress will not be accepted. 

Encore presentations will be considered if the original 

presentation was not at a national pharmacy meeting. For encore 

presentations, the original conference / date citation must be 

included on the abstract submission form. 

Accepted abstracts will be published in the final PPC 2013 

program and also in the Canadian Journal of Hospital Pharmacy. 

Authors of accepted abstracts will be notified within 3 to 4 

weeks. The majority of accepted abstracts will be presented as 

traditional posters. For PPC 2013, a small number of abstracts 

will be selected by the Educational Services Committee and the 

Research Committee to be presented as facilitated posters or 

brief oral presentations. Regardless of the type of presentation 

format, authors are responsible for their own transportation and 

accommodations at PPC. Early registration fees will apply to all 

accepted poster applications. Guidelines for traditional posters, 

facilitated posters and brief oral presentations will be provided to 

authors of accepted abstracts, as appropriate. 

Abstract Style Rules 

Title should be brief and should clearly indicate the nature of the 

presentation. Capitalize only the first letter of each word of the 

title. Do not use abbreviations in the title. List the authors, 

institutional affiliation, city, and province. Omit degrees, titles, and 

appointments. The recommended font is Times 12. 

Organize the body of the abstract according to the selected 

category as follows: 

Original Research: 

a. rationale, 

b. objectives, 

c. study design and methods, 

d. results of study including statistical analysis used, 

e. conclusion of study (which should be supported by results 

presented). 

Case Reports: 

a. rationale for case report, 

b. description of case, 

c. assessment of causality if appropriate, 

d. evaluation of the literature, 

e. importance of case to pharmacy practitioners. 

originalité, leur intérêt pour les pharmaciens et le respect des 

règles de présentation. Des directives à l’intention des auteurs et 

des exemples de résumés seront affichés d’ici peu sur le site 

Web de la SCPH à l’adresse suivante : 

www.cshp.ca/event/PPC2013. 

Si la demande ne respecte pas les exigences pour la soumission 

de résumé, y compris la soumission d’un résumé anonyme ou 

toute autre règle de présentation, cette soumission sera 

automatiquement rejetée. 

Les recherches en cours ne seront pas acceptées. 

Vous pouvez nous faire parvenir un résumé pour une affiche 

ayant déjà été présentée si la présentation antérieure n’a pas été 

effectuée à un congrès national de la pharmacie. En pareil cas, 

vous devez préciser le nom et la date de la conférence au cours 

de laquelle l’affiche a été produite sur le formulaire de 

soumission des résumés. 

Les résumés qui auront été acceptés seront publiés dans le 

programme final de la CPP 2013 et dans le Journal canadien de 

la pharmacie hospitalière. 

Les auteurs des résumés acceptés seront avisés dans un délai 

de trois à quatre semaines. La majorité des résumés choisis 

seront présentés au cours d’une session traditionnelle 

d’affichage. Pour la CPP 2013, un petit nombre de résumés 

seront choisis par le comité des services éducatifs et par le 

comité de recherche pour être présentés en affichage avec 

animation ou au cours d’une brève présentation orale. Quel que 

soit le type de format de la présentation, les auteurs doivent 

assumer leurs propres frais de transport et de logement pour la 

CPP. Tous les auteurs des résumés acceptés auront droit au tarif 

d’inscription anticipée. Des directives concernant l’affichage 

traditionnel, l’affichage avec animation et les brèves 

présentations seront fournies aux auteurs dont les résumés 

auront été acceptés, comme il convient. 

Règles de présentation 

Le titre devrait être bref et indiquer clairement la nature de la 

présentation. Seule la première lettre du premier mot du titre 

doit être en majuscule. Le titre ne doit pas contenir 

d’abréviations. Le nom des auteurs, l’établissement auquel ceuxci 

sont affiliés ainsi que la ville et la province où est situé 

l’établissement doivent être précisés, tandis que les diplômes, les 

titres et les affectations ne doivent pas être mentionnés. Il est 

recommandé d’utiliser la police Times 12. 

Le texte du résumé doit être organisé conformément aux règles 

propres à la catégorie à laquelle il appartient, de la manière 

suivante : 

Recherche initiale : 

a. justification; 

b. objectifs; 

c. méthodologie et démarche de l’étude;

35 

Pharmacy Practice: 

a. rationale for report; 

b. description of concept, service, role, or situation; 

c. steps taken to identify and resolve problem, implement 

change, or develop and implement new program; 

d. evaluation of project, 

e. the concept’s importance and usefulness to current and/or 

future practice. 

Abstract Text 

• Abstract body (not including title and authors) is limited to 

300 words. 

• A table is equivalent to 30 words. 

• A graphic is equivalent to 60 words. 

• Results or evaluation must be included in the abstract. It is not 

acceptable to state that results will be discussed. 

• Do not indent the start of a paragraph. 

• Place abbreviations in parentheses after the full word the first 

time it appears. Please keep abbreviated terms to a minimum. 

• Use numerals to indicate numbers, except to begin 

sentences. 

• Use only generic names of drugs, material, devices, and 

equipment. 

Abstracts should not include citations or reference numbers. 

For original research or pharmacy practice projects, ensure that 

the objectives, methods, analysis, results, and conclusions are 

internally consistent 

Email Confirmation of Abstract Submissions 

You should receive an email confirmation of your abstract 

submission. If you have not received an e-mail confirmation by 

the deadline, please contact Desarae Davidson by phone, 

(613) 736-9733, ext. 229. 

d. résultats de l’étude, y compris les analyses statistiques 

utilisées; 

e. conclusion de l’étude (la conclusion devrait être appuyée par 

les résultats présentés). 

Observations cliniques : 

a. justification de l’observation clinique; 

b. description du cas; 

c. analyse de la causalité, s’il y a lieu; 

d. évaluation de la documentation; 

e. importance du cas pour les pharmaciens praticiens. 

Pratique pharmaceutique : 

a. justification du rapport; 

b. description du concept, du service, du rôle ou de la situation; 

c. mesures prises en vue d’identifier et de résoudre le 

problème, d’apporter des changements, ou de créer et de 

mettre en œuvre un nouveau programme; 

d. évaluation du projet; 

e. importance et utilité du concept par rapport à la pratique 

actuelle et future. 

Texte du résumé 

• Le corps du résumé (excluant le titre et les auteurs) ne doit 

pas dépasser 300 mots. 

• Un tableau compte pour 30 mots. 

• Un graphique compte pour 60 mots. 

• Les résultats ou l’évaluation doivent être inclus dans le 

résumé. Il est inacceptable de mentionner que les résultats 

seront discutés. 

• Le début des paragraphes ne doit pas être précédé d’un 

alinéa. 

• Placer les abréviations entre parenthèses après le terme 

qu’elles remplaceront, la première fois que le terme est 

utilisé. Veuillez limiter au minimum l’utilisation d’abréviations. 

• Les nombres doivent être écrits en chiffres, sauf lorsqu’ils 

représentent le premier mot d’une phrase. 

• Seuls les noms génériques des médicaments, du matériel, 

des instruments et de l’équipement doivent être employés. 

Les résumés ne devraient pas comprendre de citations ni de 

numéros de référence. 

Dans le cas d’une recherche originale ou de projets liés à la 

pratique de la pharmacie, il faut s’assurer que les objectifs, la 

méthodologie, les analyses, les résultats et les conclusions sont 

intrinsèquement logiques. 

Confirmation par courriel de la réception du résumé 

La réception de votre résumé devrait être confirmée par courriel. 

Si vous n’avez pas reçu de confirmation par courriel avant la date 

limite, veuillez téléphoner à madame Desarae Davidson au 

(613) 736-9733, poste 229.

36 

Faculty CSHP would like to recognize the generous contributions of the following speakers: 

Conférenciers La SCPH desire souligner les généreuses contributions des conférenciers suivants : 

Carolee Awde-Sadler, BScPhm, RPh, CDE 

Peterborough Regional Health Centre 

Peterborough, ON 

Carolyn Bornstein, BScPhm, ACPR, CGP, 

FCSHP 

CSHP 2015 Coordinator 

Newmarket, ON 

Derek Naveen Chaudhary, BSc, MHSA, 

MD, FRCP(c) 



Marie Craig, BScPhm 

Southlake Regional Health Centre 

Newmarket, ON 

Carlo DeAngelis, BScPhm, PharmD 

Sunnybrook Health Sciences Centre 

Toronto, ON 

Jamie Falk, BScPhm, PharmD 


Winnipeg, MB 

Olavo Fernandes, BScPhm, ACPR, 

PharmD, FCSHP 


Toronto, ON 

Marc-André Gagnon, PhD 

School of Public Policy and Administration 

Carleton University 

Ottawa, ON 

Theresa Hurley, BScPhm, ACPR 


Halifax, NS 

Sheri Koshman, BScPhm, PharmD, ACPR 

Faculty of Medicine and Dentistry 


Edmonton, AB 

Don Kuntz, BSP 


Regina, SK 

Melanie MacInnis, BScPhm, PharmD 

Hamilton, Health Sciences Centre 

Hamilton, ON 


FCSHP 


Tucson, AZ 

Tania Mysak, BSP, PharmD 


Edmonton, AB 

Mike Namaka, BScPhm, MScPhm, PhD, 

MSMed, CA 

Faculty of Pharmacy 

Faculty of Medicine 

University of Manitoba 

Winnipeg, MB 

Kendall Nicholson, MSc 

Health Partners International of Canada 

Dollard-des-Ormeaux 

Monique Pitre, BScPhm, FCSHP 


Toronto, ON 

Giles Scofield, JD, MA 

Centre for Clinical Ethics 

Toronto, ON 

Bill Semchuk, MSc, PharmD, FCSHP 


Regina, SK 

Lauza Saulnier, BScPhm, ACPR 


Moncton, NB 

Vanessa Sherwood, BScPhm BSc(Hon) 

IWK Health Centre 

Halifax, NS 


Faculty of Pharmacy and Pharmaceutical 

Sciences 


Edmonton, AB 

Tracey Simpson, BScPhm 


Edmonton, AB 

Kathryn Slayter, BScPhm, PharmD, FCSHP 

Capital Health/Dalhousie University 

Halifax, NS 

Audrey Smycniuk, BSc(Hon), BSP, ACPR 


Saskatoon, SK 

James Tjon, BScPhm, RPh, PharmD 


Toronto, ON 

Kent Toombes, BScPhm, ACPR 


Halifax, NS 

Linda Wilhelm 

Consumer Advisory Council 

Midlands King County, NB 

Moira Wilson, BScPhm 


Saint John, MB

37 

CSHP 

Targeting Excellence in Pharmacy Practice 

ARE WE ON TARGET FOR 

PHARMACY PRACTICE 

EXCELLENCE? 

HAVE YOU HEARD ABOUT… 

u The CSHP 2015 Virtual Posters? 

Interviews with poster authors from PPC 2012 on CSHP 2015 

related projects 

u The Pharmacy Student Video Competition 2012? 

The competition is underway. Prizes for English and French 

submissions. Make this a summer student project! 

u The CSHP 2015 Hospital Pharmacy Residency 

Project Award? 

This new award is for a residency project that promotes and 

supports the implementation or achievement of a CSHP 2015 

goal or objective. 

u The CSHP Foundation’s Invitation for Research 

Grant Applications? 

Do you have a CSHP 2015 practice-related research project 

that would qualify for a Foundation research grant? Consider 

filing your grant application today! 

u The CSHP 2015 Sponsors? 

GOLD SPONSOR 

$40,000 to 59,999 

• PFIZER CANADA INC. 

BRONZE SPONSOR 

$10,000 to $19,999 

• SANDOZ CANADA INC. 

HERE’S WHAT’S COMING… 

u A Tool Kit on UNIT DOSE 

u Webinars on the Tool Kits 

u A Twitter Account to share CSHP 2015 Success 

Stories 

DONOR SPONSORS 

$1,000 to $9,999 

• PHARMACEUTICAL PARTNERS OF CANADA INC., 

A Company of the Fresenius Kabi Group 

• JOHNSON AND JOHNSON FAMILY OF COMPANIES 

• ELI LILLY CANADA INC. 

u CSHP 2015 eForum 

u The CSHP 2015 Facilities Report 2012 (from online 

survey) 

u Success Stories on the CSHP 2015 webpage

38 

Call for CSHP National Awards 

like to invite you to submit applications and nominations for the 

2012-2013 CSHP National Awards Program. The goal of the CSHP awards 

CSHPwould 

program is to improve patient outcomes by promoting excellence in 

hospital pharmacy practice. Awards are presented to pharmacists worthy of recognition for 

professional dedication and commitment to the profession and the patient. 

The program includes both individual awards as well as general awards. 

GENERAL AWARDS 

• CSHP 2015 Hospital Pharmacy Residency 

Award (NEW) 

• Management and Leadership Best Practice 

Award 

• Patient Care Enhancement Award 

• Pharmacotherapy Best Practices Award 

• Safe Medication Practices Award 

• Teaching, Learning, and Education Award 

INDIVIDUAL AWARDS 

• Distinguished Service Award 

• Isabel E. Stauffer Meritorious Service Award 

• New Hospital Pharmacy Practitioner Award 

• CSHP/CAPSI Hospital Pharmacy Student 

Award 

NOTES: For the GENERAL AWARDS program, members can 

apply for two awards per project using the general 

application form. For the INDIVIDUAL AWARDS, members 

are required to complete a separate application or 

nomination form. 

The criteria, application and nomination forms 

for these awards can be found on the CSHP 

website. 

www.cshp.ca 

The deadline for all award applications and 

nominations is Monday, September 10, 

2012 with the exception of the CSHP/CAPSI 

Student Award which is Monday, October 1, 

2012. 

For more information, please contact: 

Cheryl Mallory, CSHP’s Interim Membership 

& Awards Administrator 

T: (613) 736-9733, ext. 222 

E: membershipservices@cshp.ca

Mark your calendars for the 

PROFESSIONAL 

PRACTICE 

CONFERENCE 

BIGGEST PHARMACY CONFERENCE 

IN CANADA! F E B R U A R Y 2 - 6 • 2 0 1 3 

SHER ATON CENTRE TORONTO HOTEL • TORONTO • ON 

PROGRAM HIGHLIGHTS: 

• Awards presentation, opening ceremony 

• Pharmacy issues and controversies forum 

• Concurrent sessions 

• Workshops 

• PSN sessions 

• Satellite symposiums 

• Exhibit program 

• Career opportunities evening 

• R&E silent auction 

For more information on the conference, 

please contact: 

Desarae Davidson 

Conference & PSN Administrator 

T: 613-736-9733, ext. 229 

E: ddavidson@cshp.ca 

www.cshp.ca

40 

Exhibitor Hall Floor Plan 

Plan du hall d’exposition 

PRINCE EDWARD ISLAND 

Fire Exit 

Fire Exit 

Fire Exit 

116 

Food 

Service 

114 

112 

Posters 

113 

111 

212 

210 

Posters 

215 

213 

110 

108 

109 

107 

208 

206 

211 

209 

Plenary 

106 

104 

102 

105 

103 

101 

204 

202 

200 

207 

205 

203 

100 

201 

Exhibitor List 

Liste des exposants 

Company 

Booth 

Compagnie Kiosque # 

Alveda Pharmaceuticals Inc. ...................................................................101 

Apotex Inc......................................................................................................215 

Canadian Agency for Drug technologies in Health (CADTH) ....108 

Canadian Institute for Health Information (CIHI)...........................109 

Canadian Pharmaceutical Distribution Network (CPDN)............205 

Canadian Society of Hospital Pharmacists........................................210 

CSHP SES 2013..........................................................................................208 

Eli Lilly Canada Inc. ....................................................................................105 

Galenova Inc. ...............................................................................................212 

Hospira Healthcare Corporation.................................................204/206 

Lexicomp .......................................................................................................104 

McKesson Canada Corporation.............................................................113 

Company 

Booth 

Compagnie Kiosque # 

Mylan Pharmaceuticals ULC ...........................................................111103 

Omega Laboratories Limited..................................................................207 

Pendopharm, A Division of Pharmascience Inc. .............................116 

Pfizer Canada .............................................................................................209 

Pfizer Canada ...................................................................................200/202 

PPC, A Company of the Fresenius Kabi Group...............................203 

Pharmascience Inc. ....................................................................................114 

RxFiles Academic Detailing Program ...................................................112 

Sandoz Canada Inc. ...................................................................................201 

Servier Canada Inc. ....................................................................................106 

Shoppers Drug Mart Specialty Health Network Inc. ......................107 

SteriMax Inc. .................................................................................................111 

TEVA Canada Limited................................................................................100

Delta Prince Edward Hotel 

Floor Plan 

Plan des salles 

41

Social Events 

at a glance 

SATURDAY • AUGUST 11 

CSHP Foundation 

Golf Event 

The 2012 CSHP SES social events kick 

off with the 16th Annual CSHP 

Foundation Fundraising Golf Tournament, 

to be held at Fox Meadow Golf and 

Country Club. 

This will be the 

Foundation’s 

FINAL golf event 

at SES and we 

would like to 

see it go out 

in style. 

This major 

fundraiser 

for the 

Foundation was started 

in Ottawa in 1997. To date, we have 

made tens of thousands of dollars at this event attended by 

both golfers and non golfers from across the country. This has 

allowed the Foundation to increase the amount of money we can 

offer for both Research and Education Grants. We hope our 

members, non-members and industry partners can join us for the 

day. Remember you don’t need to be a golfer because you do 

play the best ball within your team and FUN and FUNDRAISING 

is what it is all about. It is not too late to register whether you 

have already registered for the conference or not! 

SUNDAY • AUGUST 12 

5K Fun Run, 3K Walk Event 

Work on your beach body by joining us for a 

heart-pumping 5K run or a leisurely 3K walk 

through the birthplace of Confederation. The route will take you 

through historic downtown Charlottetown and along the scenic 

waterfront by Victoria Park. All levels of fitness are encouraged to 

participate. Both routes will start and end at the Delta Prince 

Edward. Upon your return, refuel with a healthy breakfast. What a 

great way to kick-start your day! All participants will receive a SES 

on the Beach t-shirt. 

Fun Night at the Beach 

PEI North Shore 

Activités 

You will be escorted to a quiet beach on the North Shore of PEI. 

The sunset, red rocks, white sand under your feet and the calm 

relaxing sounds of the ocean will make this an unforgettable 

Island experience. Look forward to fun on the beach and a 

chance to dip your feet (or more) in the warmest ocean water 

north of the Carolinas. Local foods and entertainment will make 

this an event you will definitely not want to miss. Remember it 

can get cooler as the sun sets, so don’t forget to bring clothing 

to accommodate. 

All profits from this event will be donated to the CSHP 

Foundation, supporting the practice-based research initiatives and 

targeted education programs of CSHP’s members. Come have a 

great time with your colleagues and support the CSHP 

Foundation at the same time! 

Opening Cocktail Reception 

Delta Prince Edward Ballroom Foyer 

Kick off your Island Beach party at the opening reception. Catch 

up with friends and colleagues while sampling island treats and 

enjoying Island entertainment. What a great opportunity to try 

“Moonshine Punch” and meet the “Island’s favourite redhead”!

sociales d’un coup d’oeil 

MONDAY • AUGUST 13 

Past President’s Dinner and Dance 

Confederation Centre of the Arts 

Dress to Impress! He should wear: A summer suit or sports jacket 

with a linen shirt (no ties required), linen pants or khakis, and 

sandals. She should wear: A formal summer sundress or skirt at 

tea-or knee-length with sandals. All beach formal should be in 

white or any rainbow of pastel colours. 

Come and enjoy an evening filled with some of the best food 

and entertainment our island has to offer. The Fathers of 

Confederation will accompany you on short stroll up historic 

Great George Street to our venue. Snap a photo with Sir John 

A. MacDonald along the way if you’d like. Memorial Hall, with 

its marble-clad walls, glass ceiling and view of Province 

House will provide the perfect setting to honor CSHP Past 

Presidents. Dinner will feature a menu of delicious local surf 

and turf 

Photo credit: Discover Charlottetown

Join Us! 

CSHP M EMBERSHIP HAS M ANY ADVANTAGES 

MEMBER BENEFITS 

As a member of CSHP, you connect 

not only to a strong professional 

organization, but also to a dynamic 

network of over 3,100 hospital 

pharmacy colleagues. When you join CSHP, 

you instill fresh energy into a 65-year-strong 

association for expanding and improving 

programs and services. 

● Advocacy 

● Awards Program 

● Canadian Hospital Pharmacy Residency Board 

● Continuing Education 

● CSHP 2015 

● Partner Discount Programs 

● Fellows Program 

● Pharmacy Specialty Networks (PSNs) 

● Products and Services 

● Professional Liability/Malpractice Insurance 

● CSHP Research and Education Foundation 


Société canadienne des pharmaciens d’hôpitaux 

For more information about CSHP member benefits, please contact: 

Membership services 

T: 613-736-9733, ext. 222 | F: 613-736-5660 | E: membershipservices@cshp.ca | www.cshp.ca

Final Program - Canadian Society of Hospital Pharmacists

Create successful ePaper yourself

Delete template?

Save as template?